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Neuropeptides are the largest and most diverse class of cell-cell signaling molecules in the 
brain. They are expressed and synthesized by neurons and endocrine organs, released upon 
stimulation and act by binding to specific cell surface receptors that initiate a cascade of 
downstream signaling mechanisms. Compelling evidence from several previous studies has 
demonstrated their role in several physiological functions such as appetite regulation, nociception, 
locomotion, reproduction, learning and memory. Given their important role as the molecular 
messengers of a biological system, there is a lot of interest in the accurate identification and 
characterization of these peptides. However, the task of characterizing them comes with several 
intrinsic challenges. First, these peptides undergo rapid post-mortem degradation during the 
extraction and analysis phase. Measuring depleted levels of peptides from a vast pool of ubiquitous 
peptides and degraded proteins requires unique sampling and analytical methods. Secondly, these 
peptides have widely different physio-chemical properties with varying degrees of hydrophobicity, 
mass to charge ratio and post-translational modifications. These properties mean that there is not 
a universal analytical approach that works for all peptide characterization approaches. Lastly, prior 
structural and sequential information of these peptides is necessary to characterize them using 
traditional immunohistochemistry-based approaches. Moreover, these traditional approaches 
suffer from lack of specificity and are not inherently multiplexed in nature.  
The primary objectives of my research were twofold : 1) Develop, implement and evaluate 
liquid chromatography (LC)-mass spectrometry (MS) based workflows for optimal neuropeptide 
characterization and 2) Understand the role of neuropeptides in various neuropathological 
disorders using these workflows. This dissertation is divided into two parts. In part 1, the primary 
focus is on analytical aspects of neuropeptide characterization, discussions about the 
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pharmacological importance of neuropeptides and their measurement, the merits of various mass 
spectrometric instrumental platforms for neuropeptide characterization, the design of custom MS 
approaches for labile PTM characterization and machine learning based tools for peptide spectral 
classification. Next, the aforementioned tools and techniques were applied to elucidate the role of 
neuropeptides in chronic pain and chronic itch disorders. 
 Findings from my works will lead to better characterization of neuropeptides and advance 
our knowledge and understanding about how these cell-cell signaling molecules play a decisive 
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Introduction and summary of thesis work 
 
Neuropeptides are an important class of cell-to-cell signaling molecules that are responsible for 
neuronal communication in the central and peripheral nervous systems. They are involved in a 
variety of pathophysiological processes such as pain sensation, appetite regulation, sleep-wake 
cycle, depression, tissue regeneration and drug addiction by acting as neuromodulators, 
neurotransmitters and hormones 1-6. Due to their immensely important role in orchestrating the 
homeostatic balance of an organism, neuropeptide characterization has garnered a lot of attention 
in the latter part of the 20th century. The initial attempts to elucidate their role involved the 
utilization of molecular probe-based techniques such as immunohistochemistry and 
radioimmunoassay 7-8. In the past two decades, improvements in mass spectrometric techniques 
coupled with better separation methods and superior bioinformatics tools have led to the 
emergence of a new field-neuropeptidomics that dealt with the discovery, isolation and 
characterization of neuropeptides and expounded their role in various disease etiologies 9-12. This 
dissertation covers several aspects of neuropeptide characterization including best practices for 
sample preparation, mass spectrometric method design and data processing pipelines. The 
dissertation also covers the application of these techniques to understand the role of neuropeptides 
in diseases such as migraine, opioid-induced hyperalgesia (OIH) and chronic itch. 
Chapter 2 presents an overview of approaches/strategies for the effective development of peptides 
as drugs and the role of neuropeptides in neuropharmacology. This chapter starts with discussing 
the central role of G-protein coupled receptors (GPCRs) in maintaining the homeostatic balance 
of the body, neuropeptides that act as endogenous ligands to GPCRs and how the quest for 
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neuropeptides that act as ligands to orphan GPCR has led to the therapeutic development related 
diseases such as chronic pain 13, insomnia 14 and nausea 15. Discussions also cover the 
distinguishing aspects of neuropeptide characterization including the use of modern technologies 
such as liquid chromatography-mass spectrometry (LC-MS) for neuropeptide discovery and 
unusual routes of neuropeptide formation and function that includes include non-classical 
neuropeptides and cytosolic peptides, Endomorphins: neuropeptides without a known gene and 
non-ribosomally derived micropeptides. Finally, the chapter also highlights the lessons learned 
from nature for neuropeptide research in relevant animal models that are being adopted by the 
pharmaceutical industry.  
Chapter 3 discusses the analytical workflows for neuropeptide characterization via LC-MS based 
approaches. The chapter presents a comprehensive overview of the various stages of neuropeptide 
characterization that include: 1) post-mortem sample stabilization by heat denaturation of 
peptidases; (2) extraction of SPs from cells, tissues or releasates; (3) separation by liquid 
chromatography (LC) or capillary electrophoresis (CE); (4) detection by MS, and finally; (5) 
identification based on the MS-derived data with the assistance of bioinformatics tools 16-18. 
Various LC separations (size exclusion and reverse phase), sample ionization techniques 
(electrospray ionization (ESI) and matrix-assisted laser desorption ionization (MALDI)), mass 
analyzers (ion trap (IT), Fourier transform ion cyclotron resonance (FTICR), hybrid quadrupole 
orthogonal acceleration time-of-flight (Q-TOF), TOF/TOF and Orbitrap)  bioinformatic tools 
(Mascot, SEQUEST, X!Tandem, PEAKS studio, and Phenyx) and sample stabilization (protease 
inhibitor cocktails, instant freezing, focused microwave irradiation, hot water treatment and rapid 
conductive heating of the tissue at reduced pressures) methodologies for optimal neuropeptide 
characterization are introduced. 
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Chapter 4 describes the critical investigation of the operational mechanism of two of the most 
common mass analyzers available with the current generation of mass spectrometer: 1) quadrupole 
time of flight (QTOF) and 2) Orbitrap 19; and how the choice of an analyzer impacts neuropeptide 
characterization. Since mass spectrometers differ in resolution, sensitivity, accuracy, ways of ion 
generation, ion focusing, transfer, accumulation, fragmentation, and detection, the MS/MS spectra 
generated by these instruments differ in their spectral characteristics and ultimately affect how 
these data work with bioinformatic sequencing and identification algorithms. In addition to 
conventional evaluation metrics such as total confident peptide identifications and precursor 
protein coverage, we introduce two unique metrics to assess the spectral quality of the MS/MS 
spectra generated by i.e. 1) false discovery rate estimation based on the occurrence of known post-
translational modifications (PTMs) (peptide C-terminal amidation in this case) and 2) fidelity of 
peptide sequence identity when searched against a mixed-species protein database consisting of 
predominantly unrelated proteins. We demonstrate the role of MS instrumental platforms in 
confident neuropeptide identification and evaluate the pros and cons of each of the platforms for a 
given experimental condition. 
Chapter 5 focusses on the development of a custom MS method for characterization of labile 
PTMs. The specific focus of this chapter is on sulfated neuropeptides. Tyr-sulfation is a well-
known PTM and known to be involved specifically in modulating protein-protein and ligand-
receptor interactions 20-25. Though first characterized in the 1950s 26, localizing this PTM on a 
peptide sequence is a challenging task due to its labile nature and proximity in mass difference 
with phosphorylation (sulfation: +79.9568 Da, phosphorylation: +79.9663 Da). This chapter 
discusses in detail about the custom MS methods involving beam-type CID (high-energy C-trap 
dissociation or HCD) and electron transfer HCD (EThcD) dissociation techniques for 
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characterization of sulfation PTMs on neuropeptides. Chapter 5 also reports the confident 
localization of 4 novel sites of modification for sulfation on Secretogranin I prohormone in rats. 
Chapter 6 introduces a novel machine learning (ML) based classification method for peptide 
spectra characterization. A typical raw mass spectral file in the LC-high-resolution mass 
spectrometry (HRMS) experiments generates over tens of thousands of spectra. However, a 
sizeable portion (>90%) of these generated spectra never map to a real peptide sequence upon a 
protein database search. The computational expense of searching all the acquired spectra against 
possible peptide sequences is huge and could be prohibitively expensive when analyzing several 
hundred LC-MS runs. Chapter 6 discusses the development of a machine learning (ML) based 
technique that can learn the patterns in a true peptide spectrum match from several hundred 
thousand mass spectra and use that information to categorize spectra from a new unseen spectral 
file. This approach resulted in a 4-fold reduction in the spectral size, with only a loss of <10% of 
the true spectrum matches. This reduction in spectral size could lead to tremendous improvements 
in the overall search time for a peptide database search. 
Chapter 7 presents a comprehensive evaluation of the entire peptide repertoire associated with the 
chronic pain conditions of migraine and opioid-induced hyperalgesia (OIH). This chapter reports 
the quantification of several hundred peptides between the migraine and OIH models of mice 
compared to the controls in the regions of the brain and central nervous system associated with 
pain perception. The regions include trigeminal ganglia, trigeminal nucleus, dorsal horn, 
rostroventral medulla, periaqueductal grey, nucleus accumbens and hypothalamus. A label-free 
liquid chromatography-mass spectrometry (LC-MS) based quantitation technique was 
implemented to identify the peptide biomarkers. These measurements were done in two 
independent cohorts and only the peptides that consistently show up significant differences in both 
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the cohorts were considered truly significant. The wealth of information obtained with behavioral 
assessment was combined with MS powered quantitative peptidomics analysis of global 
neuropeptide changes and characterized alterations of endogenous peptides derived from several 
prohormones such as Pro-calcitonin gene-related peptide (Pro-CGRP), Pro-Neuropeptide Y (Pro-
NPY), Pro-Enkephalin (PENK), Pro-Opiomelanocortin (POMC) and Pro-Tachykinin (Pro-TKN) 
27,  thus laying foundation for the future functional studies and, hopefully, treatment. This is the 
first interdisciplinary study of this scale encompassing physiology, chemistry, bioinformatics and 
statistics to profile the peptidomic changes in the above-mentioned chronic pain conditions. 
Chapter 8 explores the role of neuropeptides in the transmission of itch. Similar to the approach 
described in the previous chapter, a label-free mass spectrometry-based approach was used to 
quantitatively assess the change in neuropeptide levels between the treated and control samples. 
Dorsal horn (DH) and dorsal root ganglia (DGR) that act as crucial checkpoints for transmission 
of external stimuli between the peripheral and central nervous were characterized in this study. 
Previous studies have shown that several neuropeptides, such as substance P (TAC1[58-68]; 
P41539), bradykinin (KNG1[380-388]; O08677), calcitonin gene-related peptide (CALCA[83-
119]; Q99JA0 ), neuromedin B (NMB[47-56]; Q9CR53), gastrin-releasing peptide (GRP[24-52]; 
Q8R1I2), and natriuretic polypeptide B (ANFB[103-134]; P16860) are linked to itch 28-29. The 
study described in chapter 8 is one of the first comprehensive peptidomics studies that aims to 
profile dynamics of neuropeptide level changes in DH and DRG of murine itch models. Results 
from this study can further our understanding of chronic itch mechanisms and eventually develop 
a better cure. 
Overall, this dissertation covers a range of topics that deal with every stage of a peptide 
characterization effort including sample preparation, MS method development, data acquisition, 
6 
 
data interpretation and analysis. The dissertation also discusses two cases where a successful 
combination of one or more of the analytical workflows was implemented to get a deeper 
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Pharmacological importance of neuropeptides 
2.1 Notes and acknowledgments 
 This chapter focuses on the potential of neuropeptides to act as therapeutic agents, 
their biosynthesis, and methods of characterization. The primary goal of this chapter is twofold: 1) 
to discuss analyte-specific techniques that can be implemented to profile neuropeptides from 
various neuronal tissues and 2) to discuss unusual ways in which neuropeptides have been reported 
to be formed. Both these aspects are discussed from a pharmacological point of view. This chapter 
is part of a review article under preparation titled “Neuropeptides in Neuropharmacology” to be 
published in the journal of Pharmacological Reviews. The original review paper is being co-
authored by James W. Checco, Elena V. Romanova and Jonathan V. Sweedler. The work was 











Neuropeptides, which act by binding to G-protein coupled receptors (GPCRs), have a huge 
pharmacological interest due to their central role in maintaining the overall homeostatic balance 
of the body. Several drugs were developed in the past to target neuropeptide receptors including- 
1) fentanyl and oxycodone (targeting µ-opioid receptor) for treating chronic pain 1, 2) Aprepitant 
(targeting neurokinin receptor) for treating nausea and 2, 3) Suvorexant (targeting orexin receptor) 
for treating insomnia 3. Additionally, several drugs candidates that target tachykinin, melanocortin, 
neuropeptide Y and corticotropin-releasing factor-1 (CRF-1) receptors are under development 4. 
Given that the endogenous ligands for over 25% of GPCRs are still unknown, the search for 
neuropeptide candidates that could serve as potential ligands to these receptors has gained a lot of 
interest. The approaches for discovery of such neuropeptide candidates can broadly be classified 
into two categories-1) a targeted approach where the identity of target peptide is known beforehand 
and 2) an un-targeted approach where a much wider net is cast to profile all the measurable 
peptides in the sample. The method of choice depends on several factors such as availability of 
prior information about the target peptide, abundance of the sample and whether or not the 
genome/proteome for the model of interest exists 5. 
2.3 Methods of neuropeptide discovery and characterization 
2.3.1 Probe-based methods 
The crucial role of neuropeptides and neuropeptide receptors in mediating various essential 
physiological functions has seen the rise of several analytical techniques aimed at their 
characterization. Some of the initial techniques include probe-based assays such as in-situ 
hybridization (ISH) and immunohistochemistry (IHC) for neuroanatomical localization, 
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pharmacological characterization, and functional annotation of neuropeptides and their receptors. 
For example, calcitonin gene-related peptide (CGRP), a potent vasodilator involved in 
nociception, appetite regulation and temperature regulation was extensively characterized by 
several groups via ISH and IHC 6. Better understanding regarding the localization of CGRP mRNA 
in various neuroanatomical regions and CGRP-like immunoreactivity has eventually led to the 
development of drugs such as fremanezumab, galcanezuman and erenumab for migraine that work 
by targeting the CGRP peptide and its receptor. Similarly, extensive study of the tachykinin 
receptors and their peptide ligands (Substance P, neurokinin A and neuropeptide K) using IHC and 
ISH has revealed their promising role as anti-inflammatory drugs in various neuro-inflammatory 
disorders 7.  
2.3.2 Multi-faceted omics’ 
Towards the end of 20th century, with the advancements in softer ionization techniques 
such as electrospray ionization (ESI) 8 and matrix-assisted laser desorption ionization (MALDI) 9, 
combined with improved electronics and better computational tools, mass spectrometry (MS) 
emerged as the most sought-after method for protein and peptide characterization. It’s inherently 
high-throughput nature, better sensitivity and ability characterize peptides from a complex sample 
mixture have made MS more desirable compared to other probe-based techniques such as IHC and 
ISH for peptide/protein characterization. The technical advancements in MS coupled with 
developments in other ancillary tools for arresting post-mortem peptide degradation 10-12, effective 
separation 13 and biostatistics 14 for analyzing high-volume data has led the emergence of 
‘neuropeptidomics’ — a subfield of peptidomics dedicated exclusively to the study of 
endogenously made neuropeptides.  
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Though MS is often marketed as the go-to method for peptide characterization, its utility 
as a standalone tool for neuropeptide characterization has been limited. For models without a well-
annotated genome or an extensively characterized proteome, the true potential of MS-based 
peptidomics is only realized when combined with other omics technologies such as genomics and 
transcriptomics. For example, a proteogenomic approach that involved searching the tandem MS 
(MS/MS) data against an unannotated 6-frame translation of genomic sequence was used to 
characterize a novel bioactive peptide from the marine cone snail Conus victoriae 15. This novel 
peptide, conorfaminde-Vc1(CNF-Vc1) belongs to the RF-amide class of peptides that bind to 
GPCRs with implications in a range of physiological functions, including feeding, reproduction 
and cardiovascular regulation. More recently, neuropeptide FF (NPFF-a class mammalian RF-
amide peptide) and its receptor (NPFFR2) were shown to reduce the undesirable side-effects of 
opioids in chronic pain therapy 16. 
In some cases, particularly when the entire genome of either the species of interest or the 
evolutionarily closest species is unavailable, the transcriptome of the model of interest is mined 
for putative peptide-encoding transcripts to construct a list of resulting proteins. The raw MS 
spectra are then searched against this list to identify and characterize endogenous neuropeptides. 
The neuropeptidome of the crustacean Cancer borealis was constructed in this way and the authors 
were able to predict and validate the presence of 159 novel neuropeptides 17. The identified 
peptides encompassed 20 different families including the ones such as allatostatin, tachykinin-
related peptide and FMRFamide like peptide (FLP), the mammalian equivalents of which are 
known to possess huge therapeutic potential. A similar approach was also used by Stewart et al. to 
predict and validate over 300 bioactive peptide products from two Oyster species- Pinctata fucata 
and Crassostrea gigas 18. Overall, contrary to the popular opinion that mass spectrometry is a 
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complete solution to address the challenges of peptide sequencing, its true potential is best realized 
when implemented in unison with genomics and transcriptomics.  
2.3.3 Analytic framework and bioinformatic tools 
The analysis of neuropeptides from cell and tissues is categorized into five major steps:1) 
Post-mortem tissue stabilization, 2) peptide extraction followed by desalting, 3) separation of 
analyte molecules to reduce the chemical complexity, 4) MS-based analysis and 5) peptide 
sequence identification via bioinformatic tools. 
Post-mortem degradation of peptides and proteins by proteolytic enzymes is one of the 
obstacles towards capturing the intact chemical picture of biological tissues10, 19. To ensure that 
the endogenous peptide complement is preserved intact, it is essential to arrest or delay the action 
of these enzymes. Several approaches were proposed to address this issue. Particularly, enzyme 
deactivation by rapid conductive heating of the tissue has been shown to be most effective 
compared to other methods in preserving endogenous neuropeptides 10, 19. Once stabilized, the 
tissue of interest is subjected to a peptide extraction followed by desalting to ensure that that the 
salts that interfere with MS are removed before the analysis.  
To deal with the high chemical complexity of biological specimens, techniques that can 
separate the analytes present within a sample are often coupled with MS for peptide analysis. This 
separation enables both deeper precursor-protein coverage and more accurate peptide quantitation. 
Reverse-phase liquid chromatography (RP-LC) which separates the analytes based on 
hydrophobicity, size-exclusion chromatography (SEC) 20 and strong cation exchange (SCX) 13 are 
few of the popular choices of the chromatographic platform for separations in peptidomics 
experiments. These systems are either coupled online (via ESI) or offline (via MALDI) to MS for 
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analysis. The other, albeit less widely used separation technique for sample separation is capillary 
electrophoresis (CE) 21-22. The stringent requirement for interfacing with MS coupled with limited 
commercial availability of CE systems hampered its widespread use as the choice of separation 
for peptides. Nevertheless, CE systems can handle 1-2 orders of lower sample volume making 
them a potential alternative to LC systems for cellular and sub-cellular peptidomics. Recently, 
there has been a growth in the use of a different separation technique based on the mobility of 
charged molecules within a drift tube with carrier gas called ion mobility separation (IMS) 23-24. 
Coupled with MS (IMS-MS), this technique allows for a more comprehensive peptide coverage 
by distinguishing peptides based on conformation, connectivity and topology of amino acid 
residues. Post-separation, the peptides are ionized 8-9, fragmented 25 and measured 26 by a variety 
of techniques and instrumentation types. The exact choice of these tools depends on various factors 
such as sample size, overall peptide content, existence of labile PTMs and co-occurrence of 
chemical entities such as lipids and small-molecule metabolites.  
As discussed earlier, MS based neuropeptide characterization can be categorized into 
classes-targeted and untargeted approaches 5. A distinct set of bioinformatics tools are often used 
in conjunction with the MS techniques for neuropeptide characterization. For example, statistical 
tools such as NeuroPred 27, NeuroPID 28, NeuroPIpred 29 and NeuroPP 30 are routinely 
implemented to generate a list of endogenously cleaved neuropeptides which are then used to 
validate MS findings. In case of the untargeted discovery type efforts, bioinformatics tools known 
as search engines are used to deduce neuropeptide sequences from the raw MS spectra 31. These 
search engines deduce the peptide sequence either solely based on the peptide fragmentation 
pattern (known as denovo search) or by comparing the acquired MS spectra to an existing proteome 
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database (known as database search). Some of the newer search engines such as PEAKS Studio32 
perform a hybrid search that combines the strengths of denovo and database methods. 
2.3.4 Characterization of unusual PTMs 
Neuropeptides often undergo a series of post-translational modifications (PTMs) before 
attaining their final bioactive form. For example, C-terminal amidation of several neuropeptides 
such as CGRP, Substance P, Neuropeptide Y, etc., is essential for maintaining their biological 
activity 33. Similarly, the N-terminus of thyrotropin-releasing hormone (TRH) is modified by 
pyroglutamate and the C-terminus by amidation 34. Similarly, phosphorylation plays a decisive 
role in inhibition of bacterial growth 35, proteolytic processing of gastrin precursor 36 and the 
binding affinity of α-MSH towards melanocortin receptors 37. Even the active peptide components 
of cone-snail venoms have a high-degree of disulfide bonds that are essential for maintaining their 
functionality 38. Characterizing peptides with such modifications often requires custom-designed 
approaches tailored specifically to target the PTM of interest. For example, in case of sulfation, in 
addition to being a labile PTM, it also results in a very similar mass change as phosphorylation 
(+79.9663 Da for phosphorylation and +79.9568 Da for sulfation). To overcome these challenges, 
we 39 and others 40 have successfully designed and implemented custom MS fragmentation 
approaches to characterize sulfated PTMs in complex sample matrices. Γ-carboxylation of 
glutamate is another example of an unconventional PTM, particularly in invertebrates. Though 
highly prevalent in mammals, γ-carboxyglutamate was discovered as a cell-cell signaling molecule 
by our group in 2006 41. In this work, we were able to successfully localize the modification on 
the glutamate using the collective information from isotopic labeling, tailored collision energies 
and enrichment via prefractionation.  
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Isomerization of L-amino acids to their D counterparts results in peptides (rightly referred 
to as D-amino acid-containing peptides-DAACPs) with higher bioactivity and better resistance 
towards enzymatic degradation. Despite its high-functional importance, characterizing DAACPs 
via MS is a  challenging task due to the zero-mass change associated with the PTM. We and other 
researchers worldwide have developed several approaches such as enzyme assisted MS screening 
42, metal-assisted characterization via kinetic method 43 and more recently, IMS-MS to characterize 
these modified peptides 23-24. 
2.4 Unusual routes to peptide formation and function 
Historically, researchers assumed that only peptides that followed a set of rules could be 
classified as a cell-cell signaling agents, viz., i) synthesized via the secretory pathway and released 
upon stimulation, ii) specificity towards receptors on target cells and elicit downstream chemical 
changes upon binding, iii) regulated in the temporal and/or spatial domain and iv) reuptake or 
recycled post usage. However, there has been an increasing occurrence of examples of peptides 
that perform the role of a signaling peptide but violate one or more of the above-stated rules. Here, 
we have discussed a few examples that challenge this conventional dogma of what makes a 
signaling peptide. 
2.4.1 Non-classical neuropeptides and cytosolic peptides 
Contrary to the popular opinion that neuropeptides are derived from larger precursor 
proteins, packaged into vesicles and released upon stimulation, there has been substantial evidence 
of bioactive peptides that do not follow this route and are derived from the angiotensinogen by the 
action of angiotensin-converting enzyme 44. In the following decades, there have been even more 
discoveries of non-classical and cytosolic peptides such as hemorphins 45, hemopressins 46, 
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hippocampal cholinergic neurostimulating peptide (HCNP) 47 and diazepam binding inhibitor 48. 
In this review, we will discuss hemopressins and hemorphins in greater detail.  
Hemopressin, a nonapeptide (PVNFKFLSH) derived from the α-chain of hemoglobin, has 
been shown to elicit a dose-dependent nociceptive and anti-hypertensive behavior in mice49. 
Additionally, the hemopressin peptide binds to the endocannabinoid receptor (CB1), whose role 
in physiological processes such as addiction, pain, memory, appetite, cognition and behavioral 
response to reward and stress is well-established 50. Though hemopressin looks promising as a 
potential drug candidate due to its various therapeutic properties and likely role in several 
physiological processes, it is still uncertain as to whether it is an endogenous peptide or a cleavage 
product of one of the longer, yet bioactive forms 51. Further systematic efforts to elucidate the 
mechanistic pathway for its biosynthesis are required to utilize the therapeutic potential of 
hemopressins. 
Hemorphins are a group of short peptides, ranging in size from 4-10 residues, derived from 
the N-terminus of the β chain of the hemoglobin and consist of a central YPWT core. They are 
known to show affinity towards opioid receptors with the serum and plasma levels were correlated 
with muscle fatigue 52, obesity 53 and diabetes 54. Given their involvement in various 
pathophysiological processes, the inquiry into the biosynthesis and regulation of hemorphins has 
garnered a lot of interest in the recent past. Though the exact mechanism of their regulation is not 
yet understood, work published by Feron et al. has shown that plasma levels of LVV-hemorphin, 
a quintessential hemorphin, are correlated with levels of enzymes cathepsin D and dipeptidyl 
peptidase IV (DPP IV) 54. However, as is the case with hemopressins, further studies need to be 
performed to elucidate the mechanistic pathway for hemorphin regulation. 
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2.4.2 Mysterious endomorphins: neuropeptides without a known gene 
The opioid-receptor system in mammals controls the pain and the reward pathway. Several 
peptides such as β-endorphins, enkephalins and dynorphin in the mammalian central and 
peripheral nervous system have been shown to act as endogenous ligands towards the opioid 
receptors 55-56. Additionally, non-peptide alkaloid opiates such as morphine are known to bind to 
the µ-opioid receptor with the highest affinity 57. Though morphine is a potent analgesic, repetitive 
usage leads to several side-effects such as tolerance, hyperalgesia, respiratory-depression and 
constipation to name a few. The quest to find alternate µ-opioid receptor ligands that can elicit the 
same analgesic effect as morphine without having the undesired side-effects led to the discovery 
of endomorphins (EMs) in 1997 58. Originally isolated from the bovine frontal cortex, EMs include 
two tetrapeptides (EM-1:YPWFa and EM-2: YPFFa) that are shown to be present in most 
mammalian species including primates and rodents 59. EM-1 and EM-2 also happen to be the first 
known, endogenously made peptide-ligands that target the µ-opioid receptor. 
Moreover, their antinociceptive property combined with the absence of major side-effects 
has spawned several follow-up studies that further explored the usefulness of EM-1/EM-2 and 
their analogs as potential therapeutic agents 60. One such analog developed by the Zadina group 
(codenamed ZH853) showed great promise with a superior analgesic effect compared to morphine 
along with reduced time spent in the chronic pain state accompanied by lack of latent sensitization. 
This superior analgesic property combined with the significant reduction in the above-mentioned 




Even though EM and its analogs have advantages over conventional alkaloid-based 
analgesics such as morphine, the exact biosynthetic route for EMs is still unclear 61. For a 
protein/peptide synthesized via the conventional ribosomal pathway in a model organism, the 
genome should contain the corresponding protein-encoding gene. However, there is no evidence 
yet to support the presence of an EM encoding gene. Currently there are two competing hypotheses 
that try to address this problem: 
2.4.2.i) Denovo synthesis of EM from the constituent peptide building blocks: In this 
hypothesis, the authors 62, have proposed a de novo synthetic route for EM-1 and EM-2 in a non-
ribosomal fashion via the reverse catalysis of peptidehydrolase with the dipeptide Tyr-Pro and the 
individual amino acids (Trp and Phe) as the starting components. Though this hypothesis seems 
plausible, non-ribosomal peptide synthesis via reversal of peptidehydrolase is not conformed yet 
in eukaryotes. Moreover, both EM-1 and EM-2 are α-amidated and the only known mechanism by 
which this can occur endogenously is inside a dense-core vesicle 63 and the proposed de novo 
synthetic does not concur with this existing knowledge. In light of such discrepancies, a more 
rigorous analytical approach backed with robust experimental validation would be required to 
strengthen the proposed hypothesis. 
2.4.2.ii) Biosynthesis for EM-1 from the oxidative modification of a transcript encoding 
analogous peptides: Here, the authors 64 suggest that a stress-induced oxidative modification of 
the G nucleobase in the DNA leads to a transversion of G→T where the modified segment now 
encodes for YPWF (EM-1). Though this type of stress-induced nucleobase oxidation is a well-
known phenomenon in both DNA and RNA sequences 65, the sequence specificity for such non-
enzymatic stress-induced oxidation is unclear. Further validation of the specific conditions that 
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lead to such site-selective oxidations is required before one could conclude the viability of this 
proposed hypothesis. 
Overall, though Ems show a great promise as an alternative to the alkaloid analgesics such 
as morphine, a better understanding of the endogenous synthesis and regulation could help to 
further enhance their therapeutic potential.    
2.4.3 Microproteins and small ORF coded peptides 
The central dogma of molecular biology is the process of information flow from genes to 
protein (DNA → RNA → Protein). An open reading frame (ORF) of the mRNA has a set of codons 
that code for specific amino acids. The start codon, AUG, signals the beginning of protein 
translation and the stop codons (UAG, UAA, and UGA) signal its end. Since a long ORF typically 
has a higher chance of coding for a protein, most ORF-finding algorithms set a cutoff at 300 
nucleotides (100 amino acids) for the lower limit of detection. Moreover, mRNA stretches that do 
not have start codons and/or lack evolutionary similarity to other known ORFs are also 
disregarded. Therefore, several stretches of RNA may be incorrectly classified as non-coding. 
However, studies performed by independent groups have shown that several of these non-coding 
RNA sequences (ncRNA) and short open reading frame (smORFs) do encode for peptides termed 
as micropeptides that are biologically active 66-68. These bioactive small ORF coded peptides 
(SEPs), or micropeptides, are produced directly from ribosomal translation instead of 
posttranslational proteolytic processing of the precursor protein. A combination of computational, 
genomic and proteomic approaches is extensively used to identify and characterize these peptides 
69. Despite the discovery of several SEPs over the past few decades, their exact functional role is 
uncertain. Here, we discuss few of the SEPs whose functional role has been ascertained.  
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One of the first functionally characterized SEPs is from the model organism Drosophila 
melanogaster. These SEPs are derived from a previously thought non-coding polycistronic tarsal-
less(tal)-gene and have been shown to play a role in the embryonic development of Drosophila 67. 
In E.coli, a smORF called SgrS has been shown to encode a 43-residue SEP named SgrT, which 
inhibits glucose transport 70. More recently, bioactive SEP named myoregulin (MLN) was 
discovered in rodents. MLN has been shown to regulate muscle relaxation by controlling Ca+2 
influx pumps 66. Additionally, SEPs have also been shown to be involved in DNA repair and 
inhibition of tumorigenesis 71. smORFs and SEPs represent a new and emerging area of study in 
the realm of bioactive/signaling peptides which are still largely unexplored 68. Moreover, SEPs 
could also potentially interact with orphan GPCRs making them a desirable target for drug 
development. With the latest advancements in bioinformatics, we could see even more smROFs 
and SEPs being uncovered. This new class of bioactive peptides could provide deeper insights into 
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Signaling peptides (SPs), which include many different types of endogenous peptides such as 
neuropeptides and peptide hormones, are involved in the regulation of various biological functions 
and behaviors 1-4. Identifying the cell-cell SPs in tissues and cells provides a basis for 
understanding these numerous physiological processes and biological phenomena; however, the 
chemical analysis of SPs is challenging because of the inherent structural and chemical complexity 
of the central nervous system, especially in mammals. Neuropeptides are produced via a series of 
enzymatic processing steps from protein precursors known as prohormones 5. A single prohormone 
can encode multiple bioactive peptides, either replicates of an individual peptide, or single copies 
of different peptides, or both. Mass spectrometry (MS)-based platforms are well-suited for the 
discovery and unambiguous characterization of bioactive peptides, as nearly all post-translational 
modifications (PTMs) result in characteristic mass shifts.  
Peptidomics, a term introduced by several groups in 2001 6-8, is a field of study that aims to 
simultaneously identify the peptide complement of cells, tissues, organs or an entire organism. 
Neuropeptidomics refers to the detailed analysis of endogenous peptides from the brain or other 
neuronal tissues, and can be considered a subfield of peptidomics. A typical peptidomics analysis 
of SPs usually consists of five major steps (Figure 3.1): (1) sample stabilization by heat 
denaturation of peptidases (2) extraction of SPs from cells, tissues or releasates, (3) separation by 
liquid chromatography (LC) or capillary electrophoresis (CE), (4) detection by MS, and finally, 
(5) identification based on the MS-derived data with the assistance of bioinformatics tools 1-2, 9-10. 
This chapter outlines the most common and effective protocols based on the mass spectrometry 
based neuropeptidomics studies published in the literature 11-16. 
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Sample preparation is a crucial step in characterization of neuropeptides. No matter the 
technical figures of merit of the instrumentation used to characterize the peptides, if the methods 
used to sacrifice the animal and isolate the tissue are not done well, the measurements will not 
succeed. It is essential to minimize the post-mortem proteolytic degradation of proteins and 
peptides, especially for mammalian brain samples. These proteolytic events can be delayed or 
minimized by the use of protease inhibitor cocktails 17, instant freezing 18, heat inactivation of 
snap-frozen samples 18-19, focused microwave irradiation 20, treating with hot water 3, 10 or by 
deactivating the enzymes by rapid conductive heating of the tissue at reduced pressures 11, 13. Rapid 
conductive heat inactivation of the tissues has particularly shown to be more effective over other 
methods in preserving the endogenous complement of the peptidome 11. While both intact tissues 
and tissue homogenates have been used in neuropeptidomics studies, this chapter focuses on the 
latter strategy. Multi-stage peptide extraction most often is based on the use of organic solvents in 
combination with strong acids; strategies that employ a series buffers with different pH and 
polarity to improve the peptide’s recovery from the sample have become popular as well 3, 11, 21. 
Additional sample preparation steps, such as desalting of the extracts, can also be helpful.  
To reduce the complexity of the tissue homogenate or peptide extract, a chromatographic 
separation is often employed before the MS analysis. Owing to the relatively hydrophobic nature 
of peptides, a reversed-phase liquid chromatography (RPLC) 18 is most commonly employed. 
Sometime, a strong cation exchange (SCX) based column is coupled with an RPLC column to 
ensure maximum peptide separation (Figure 3.2). Various LC/MS platforms have been used in 
neuropeptidomic studies. Depending on the ion source, LC can be coupled to MS either online 
(electrospray ionization (ESI) source) or offline (matrix-assisted laser desorption/ionization 
(MALDI) source). Mass analyzers commonly used in neuropeptidomics include ion trap (IT) 22-24, 
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Fourier transform ion cyclotron resonance (FTICR) 23, 25, hybrid quadrupole orthogonal 
acceleration time-of-flight (Q-TOF) 26-28, TOF/TOF 10, 23, 29 and Orbitrap27, 30. Most of these 
systems are capable of alternating MS and tandem MS (MS/MS) scans automatically in a data-
dependent manner.  
Bioinformatics tools play a vital role in the processing of MS-derived data; in general, they 
serve two important purposes--as a tool for the discovery/prediction of putative prohormone genes 
in newly sequenced genomes and as a tool for the identification of SPs to confirm/validate the 
predicted prohormones and peptides. The availability of genomic, transcriptomic, and proteomic 
information for a growing number of species allows in silico discovery of prohormones in newly 
sequenced species. Sequences of known prohormones from other species can be used to survey a 
nascent genome to find prohormone genes that were not previously known 31. The construction of 
a neuropeptide prohormone database is the first step in peptide identification. The most likely set 
of putative SPs can be predicted from annotated prohormones using several binary logistic and 
expert system tools such as the NeuroPred discovery tool 32-33. A library of predicted peptides can 
aid in the follow-up MS analyses.  
Bioinformatic algorithms identify peptides from their fragmentation spectra based on two 
basic principles: 1) spectrum match to in silico peptide library also known as database search, and 
2) de novo sequencing. In a database search, the algorithm identifies the peptide sequences by 
matching the generated MS/MS spectra to a list of peptides and proteins within a specified 
database. A variety of bioinformatic tools such as Mascot 34-35, SEQUEST 36-37, X!Tandem 38-39, 
PEAKS studio 9, 40, and Phenyx 41, have been developed to assist with this task. The main 
difference between a typical bottom-up proteomics experiment and peptidomics analysis of 
endogenous peptides is the lack of enzymatic digestion step during sample preparation. Therefore, 
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database search parameters should account for this difference and “no enzyme” option is chosen 
in search parameter setup page of most bioinformatics platforms. Different scoring algorithms of 
the above-named tools result in different probability scores from each platform, and careful 
attention must be given to interpreting the data and comparing the outputs from the various 
platforms utilized. In this chapter, I primarily focus on the database search process w.r.t the 
software PEAKS. However, the other search engines have a similar operational workflow. 
For the MS/MS mass spectra that cannot be assigned via automatic protein/peptide database 
searches, de novo analyses of fragmentation patterns and mass shifts characteristic are performed. 
In a de novo approach for peptide sequencing, the algorithm constructs the peptide sequence 
exclusively based on the fragmentation pattern of the obtained MS/MS spectra. The fragmentation 
patterns and mass shifts characteristic of ion series from N- and/or C-termini are generated which 
serve to generate sequence tags for unassigned MS/MS mass spectra of putative peptides. Obtained 
sequence tags can then be used to survey the sequenced genome of that species (which can be the 
first step in the discovery of novel prohormones), or to probe for prohormones in other species 
using homology searches. Some of the well-known de novo sequencing programs include 
SHERENGA 42, Lutefisk 43, NovoHMM 44, PepNovo 45 and pNovo46. This chapter illustrates the 
major steps of both de novo and database sequencing based on collision-induced dissociation 
(CID) fragmentation spectra as an example; MS/MS spectra obtained via other fragmentation 







3.3.1 Sample stabilization 
The dissected tissue is stabilized to ensure the enzyme degradation is halted. One of the best 
ways to do this is via a rapid conductive heating-based approach by Denator Stabilizor 11. The 
tissue is either directly stabilized post dissection or snap frozen with liquid nitrogen for immediate 
storage and then stabilized using the Stabilizor before use. Once the stabilization is complete, the 
tissue is removed from the Stabilizor and placed in the peptide extraction buffer. 
3.3.2 Peptide extraction 
Usually, a series of extraction buffers are used to ensure maximum peptide extraction from 
stabilized tissues. In this chapter, I discuss a three-stage extraction buffer. First, the stabilized 
tissue is homogenized in LC-MS water (pH 7) on a bed of ice and incubated for 1 h. The 
homogenate is then centrifuged for 20 min at 14,000 rpm and 4°C and the supernatant is transferred 
to a new microcentrifuge tube. A second buffer, acidified acetone (40:6:1 acetone/water/HCl) or 
acidified methanol (10% glacial acetic acid in methanol) is added to the solid pellet, vortexed for 
1 min, and kept on ice for 1h. The homogenate is again centrifuged for 20 min at 14,000 rpm at 
4°C in a microcentrifuge tube to pellet any solid material and the supernatant is combined with the 
first stage extract. A third extraction buffer of ice cold 0.25% (v/v) acetic acid/ H2O is added to 
the remaining solid pellet vortex for 1 min. and kept on ice for 1 h. The homogenate is centrifuged 
for 20 min at 14,000 rpm at 4°C and the supernatant is mixed with the supernatants from the 




3.3.3 Desalting  
Desalting for peptide samples is usually performed via solid phase extraction (SPE) using silica 
beads with C18 alkyl chain derivatives as the stationary phase. Briefly, the sorbent is activated 
with 50% H2O/50% CH3CN /0.1% FA and 0.01% TFA (v/v/v/v) followed by equilibration with 
95% H2O/5% CH3CN/0.1% FA and 0.01% TFA (v/v/v/v). Once equilibrated, the sample 
(dissolved in the same solvent as the one used for equilibration) is loaded onto the SPE column. 
The loading is usually repeated 4-5 times to ensure maximum peptide retention onto the stationary 
phase. Once the loading is finished, the SPE column is then washed with 95% H2O/5% 
CH3CN/0.1% FA and 0.01% TFA (v/v/v/v) to remove the salts. The peptides are then eluted with 
30% H2O/70% CH3CN/0.1% FA and 0.01% TFA (v/v/v/v), dried in a vacuum concentrator and 
reconstituted with 95% H2O/5% CH3CN/0.1% FA and 0.01% TFA (v/v/v/v) before LC-MS 
analysis. 
3.4  LC-MS analysis 
Appropriate sample volume (usually between 5-10 μL) is loaded onto a C18 pre-column trap 
of the LC. After the sample loading (typically 3-4 minutes), the trap column is switched in-line 
with the reverse phase C18 analytical column. Peptides are separated on the analytical column 
with a gradient using solvent A (H2O with 0.1% FA) and B (ACN with 0.1% FA). The gradient is 
usually determined by the elution profile of the target analytes. The LC eluent is interfaced online 
with the ESI source of a mass spectrometer. In a typical peptidomics experiment, the samples are 
run in a data-dependent acquisition method to trigger the MS/MS scan. Here, the most intense 
ion(s) in the MS scan are selected as parent ions for fragmentation. The collision energy is also 
adjusted to ensure most efficient and reproducible MS/MS fragmentation. The MS/MS scans are 
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typically performed in the range of 50–2000 m/z. Most Orbitrap mass spectrometers have 
fragmentation modes in addition the collision induced dissociation (CID) such as the Electron 
transfer dissociation (ETD) and High energy collisional dissociation (HCD). There modes can 
either be used individually or in combination with one or more other modes depending on the 
requirement. Additional parameters related to the ion injection value, resolution of analysis and 
collision energy for fragmentation can be chosen depending on the type of sample being analyzed. 
3.5  Data analysis 
Post-acquisition, the raw MS/MS data is converted to a universal format, such as the Mascot 
generic file format (.mgf) , the peak list format (.pkl) or RAW (.raw) for further downstream 
analysis. A set of search parameters including precursor and fragment mass tolerance (10 ppm and 
0.1 Da respectively for a typical ESI-Orbitrap based experiment), enzymatic digestion (mostly 
trypsin for bottom-up proteomics and none for an endogenous peptide discovery experiment), 
target protein database and the allowable post-translational modifications (PTMs). The range of 
PTMs commonly incorporated into a peptidomic search include acetylation (K, N-terminal), 
oxidation (M), phosphorylation (S,T,Y), pyrrolidone (Q and E), amidation (C-term) and half-
disulfide bond (C). Once the search is complete, the resultant peptide sequences are filtered using 
a set false discovery rate (FDR) threshold for accounting for the occurrence of random peptide 
spectrum matches (PSM). This FDR cutoff depends on the exact nature of the experiment. 
However, 1% FDR at the PSM level is a commonly used filtering cutoff.     
The peptides identified from the database search can further be used for label-free relative 
quantitation. Software tools such as Skyline 47, MaxQuant 48 and Mascot 49 are some of the widely 
used software tools for label-free peptide quantitation. While Skyline and MaxQuant match the 
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peptide IDs to the corresponding MS1 extracted ion chromatograms (EIC) and calculate the area 
under EIC for quantitation, Mascot performs the quantitation directly from the MS/MS data by 
comparing the spectral counts of each peptide. These tools match the parent ion mass, isotopic 
pattern and retention time of the library peptides with the sample to confirm their identity.   
3.6 Conclusion and future perspectives 
 Monumental developments over the past few decades in the areas of sample stabilization, 
peptide extraction, chromatographic separation, mass spectrometric instrumentation and 
bioinformatic tools have led to remarkable advancements in the field of neuropeptide 
characterization. The tools, techniques and methods discussed in this chapter give a comprehensive 
overview of a typical neuropeptide characterization workflow including best practices for sample 


















Fig. 3.2:  Schematic diagram of the online SCX-RPLC setup. Adapted with permission from 

























Table 3.1 Fragment ion series of different types of MS instrument. Adapted from the Matrix 
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Table 3.1 (cont.) 
 
z+H ions   X  X  
z+2H ions   X  X  
d or d' ions†      X 
v ions      X 
w or w' 
ions† 
     X 
 
†: Isoleucine and threonine are doubly substituted at the beta carbon, so that side chain loss can 
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Neuropeptides are expressed and secreted by neurons and neuroendocrine organs, act as 
cell-to-cell signaling molecules, and are involved in a range of physiological processes, e.g., 
feeding, reproduction, locomotion, memory, and learning 1-6. Neuropeptides are produced by post-
translational prohormone processing of larger precursor proteins via multiple steps of enzymatic 
cleavage, followed by additional modifications (Figure 4.1) 7. Since the 1990s, mass spectrometry 
(MS)-based characterization of peptides and proteins has played a vital role in understanding 
numerous physiological processes and disease states in models ranging from unicellular organisms 
to complex mammalian systems, with hundreds of peptides identified and characterized 8-12. This 
progress has been made possible due to advancements in instrumental capabilities and 
computational tools for peptide sequencing and identification, as well as the development of robust 
workflows and peptide discovery strategies 13. The speed, sensitivity, resolution, and dynamic 
range capabilities of modern mass spectrometers make them effective tools for peptide discovery 
and characterization.  
Given the distinct operational mechanisms and performance specifications of the mass 
analyzers available today, the analytical platform selected for peptide and neuropeptide 
identification is important, with decisions made according to experimental goals. Because mass 
spectrometers differ in resolution, sensitivity, accuracy, means of ion generation, ion focusing, 
transfer, accumulation, fragmentation, and detection, the produced tandem MS (MS2) data may 
differ in ways that ultimately affect how these data integrate with bioinformatic sequencing and 
identification algorithms. Elias et al. 14  have shown that peptides identified exclusively by ion 
trap-based mass spectrometers are on an average twice as long as peptides identified by quadrupole 
(Q)-time-of-flight (TOF) instruments. They also reported the percentage of confidently assigned 
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MS2 spectra to be 50% higher for ion trap compared to Q-TOF analyzers. Thus, different platforms 
may be biased toward preferential detection of molecules with specific physiochemical properties, 
even from the same sample. In addition to variations in mass spectrometer configurations and 
technical aspects of MS2 data acquisition, bioinformatic requirements play a significant role in 
successful peptide identifications that drive discovery.  
The goal of this work was to assess the technical advantages of several common 
instrumental platforms and mass spectrometric methodologies targeting neuropeptidomic 
applications. We analyzed peptide extracts from the abdominal ganglion of the mollusk Aplysia 
californica, a relatively simple animal model with a ganglionic nervous system comprised of 
~20,000 neurons, which can be sampled selectively and reproducibly. Hundreds of Aplysia 
neuropeptides from numerous prohormones have been characterized by MS, with many localized 
to the abdominal ganglion. Moreover, a wealth of neuropeptide expression data is available for 
Aplysia 15-18, allowing for an informed assessment of the neuropeptide identification results 
collected from the various MS platforms tested here. 
The criteria used to assess platform performance are based on bioinformatic outcomes 
when using automatic interrogation of the MS2 data obtained from each instrumental platform and 
compared against the Aplysia protein database from UniProt19. We tabulated metrics such as the 
number of unique peptides and more specifically, mature, full-length neuropeptides, neuropeptide 
precursor protein coverage by detected peptides, mass range of the peptides detected, and 
percentage of peptide false-positive hits judged by the validity of a well-understood post-
translational modification (PTM).  
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The term PTM usually refers to a covalent chemical change on proteins and peptides, which 
may turn the peptide molecule bioactive by improving its receptor binding or lifetime 20-22. 
Molecular mechanisms of PTM are often highly conserved across different species. Here we 
evaluate the validity of one such PTM, C-terminal amidation, widely represented among known 
Aplysia neuropeptides and other animals, and identified in our experiments across different 
platforms. Significant experimental evidence on the in-vivo mechanism of peptide amidation 
indicates the only known mechanism for C-terminal amidation of polypeptides requires the 
presence of glycine on the C-termini. This glycine is acted upon by two enzymes, peptidylglycine 
alpha-hydroxylating monooxygenase and peptidyl-alpha-hydroxyglycine alpha-amidating lyase, 
in tandem, or a single combined enzyme, peptidyl-glycine alpha-amidating monooxygenase. Both 
processes result in the removal of glycine and the formation of a C-terminal amidated peptide with 
the loss of a glyoxylate anion 23. Unfortunately, virtually all peptide-sequencing software packages 
consider only the mass shifts associated with substitution of a carboxyl group by an amine group 
amino residue amidation, regardless of whether this residue is preceded by glycine. Manual 
curation of automatically generated data for false PTM assignments, as reported in the current 
work, changes statistically reported false discovery rates (FDRs) and illuminates the biological 
merit of peptidomic results. This PTM-based evaluation of results is one unique aspect of the 
current work. Though there have been studies in the past that evaluated the performance of 
different mass spectrometric platforms and bioinformatic search algorithms 24-26, there have not 
been many efforts to assess the spectral characteristics of data acquired by different platforms 
based on the actual identity of detected peptides that used in-depth biological information on 
peptide formation. The PTM-based approach presented here evaluates whether the automatically 
deduced peptide structures are feasible from a biological standpoint.  
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In addition to the FDR estimation via known PTMs, we tested the fidelity of automatic 
peptide identification by searching the MS2 data against a mixed species database containing 
protein entries from Homo sapiens in addition to A. californica. The H. sapiens database serves as 
a ‘dummy database,’ as described by Jeong et al. 27, from which no significant peptide spectrum 
match (PSM) is expected; however, the total number of PSM matches crossing a specific threshold 
are now reduced due to the increase in the size of the database. This reduction in the number of 
identified PSMs in part depends on the spectral quality acquired by the mass spectrometer, and 
may vary for different MS platforms. Data sets with high-quality spectra are likely to have fewer 
reductions compared to low-quality spectra. Moreover, the probability of a non-random match 
between the MS2 spectra and peptide sequence within a database depends on the size of the 
database 27. Hence, a higher quality MS2 spectra would be required to selectively identify A. 
californica peptides from a list of predominantly irrelevant proteins.  
The first of two instruments used was an Orbitrap Fusion Tribrid mass spectrometer 
(ThermoFisher Scientific, Waltham, MA, USA); the flexibility offered by this system allowed us 
to test different combinations of molecular fragmentation modes and analyzer types for fragment 
ion analysis (MS2). Three combinations were used with the Fusion for MS2: (1) high-energy 
collisional dissociation with Orbitrap (HCD-OT); (2) high-energy collisional dissociation with ion 
trap (HCD-IT); and (3) collision-induced dissociation with ion trap (CID-IT). Collision-induced 
dissociation with the Orbitrap (CID-OT) for MS2 was not evaluated as it has been shown that the 
ion routing mechanism for this method leads to suboptimal performance of the instrument 25. The 
second instrument was an Impact HD Qq-TOF mass spectrometer (Bruker, Billerica, MA), used 
to test collision-induced dissociation time-of-flight (CID-TOF) for MS2. We demonstrate that the 
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identification results, as judged by FDRs and biological merit, are influenced by the instrumental 
platform used for data acquisition.  
4.3 Experimental 
4.3.1 Animals  
Aplysia californica were obtained from the NIH/University of Miami National Resource 
for Aplysia (Miami, FL) and housed in a tank with aerated, circulated, filtered, and chilled to 15 
ºC artificial seawater prepared from Instant Ocean Sea Salt (Instant Ocean, Aquarium Systems 
Inc., Mentor, OH) dissolved in purified water. Four animals weighing 120–140 g were used for 
the current study.  
4.3.2 Peptide extraction  
Animals were anesthetized by injection of isotonic MgCl2 (~50% of body weight) into the 
body cavity. Abdominal ganglia were quickly dissected, incubated for 30 min at 34 ºC in 10 
mg/mL protease IX solution in artificial seawater (ASW) to soften the connective tissue (ASW: 
460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 26 mM MgSO4 and 10 mM HEPES 
in Milli-Q water (Millipore, Billerica, MA), pH adjusted to 7.8). Treated ganglia were rinsed in 
ASW supplemented with 100 units/mL penicillin G, 100 µg/mL streptomycin, and 100 µg/mL 
gentamicin, transferred into a vial with 100 µL of ice-cold acidified acetone (acetone:water:formic 
acid (FA) 40:5:5), and homogenized using a mechanical pestle (Kontes Pellet Pestle Motor, 
Thermo Fisher Scientific). The homogenate extraction was placed on ice for 30 min followed by 
centrifugation at 14,000 × g. The supernatant was collected, vacuum dried at room temperature 
(24 ºC) and stored at –20 ºC until further analysis. For liquid chromatography (LC)-MS analysis, 
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the dry sample was reconstituted in 100 µL of 0.1 % FA in LC-MS grade water; 5 µL of this 
reconstituted sample was used for each of the technical replicates. 
4.3.3 Peptide extract separation with nanoLC  
LC was performed with a Dionex Ultimate 3000 RSLC with a nanoflow selector (Thermo 
Fisher Scientific). The separation method was kept consistent across the different MS instruments 
and configurations to ensure reproducible separation. The sample was loaded onto a C18 Acclaim 
PepMap µ-Precolumn trap (5 µm; Thermo Fisher Scientific) with a loading solvent (99% water, 
1% acetonitrile (ACN), 0.1% FA, 0.01% trifluoroacetic acid) at 15 µL/min for 3 min. The trap was 
switched in line with the analytical column an Acclaim PepMap RSLC column (C18, 75 µm × 150 
mm, 2 µm, 100Å; Thermo Fisher Scientific), and sample separated at a uniform flow rate of 300 
nL/min using 0.1% FA in LC-MS grade water (solvent A) and 0.1% FA in LC-MS grade ACN 
(solvent B) as the mobile phase. The flow gradient conditions were: 0–3 min, 1–1% B; 3–6 min 
1–10% B; 6–90 min, 10–70% B; 90–100 min, 70–99 % B; 100–110 min 99–1% B; 110–120 min, 
1–1% B.  
4.3.4 Mass spectrometric measurements  
A Bruker IMPACT HD QqTOF mass spectrometer outfitted with a CaptiveSpray 
nanosource was used in MS2 mode with CID fragmentation. The data were acquired over a range 
of 300–3000 m/z in a top speed data-dependent mode with a cycle time of 3 sec. Precursor ions in 
the range of +1 to +4 were considered. A fixed MS1 scan rate of 4 Hz, and a variable MS2 scan 
rate of 8Hz for low intensity (5000 per 1000 sum) and 16 Hz for high intensity (100,000 per 1000 
sum), were used. Collision energy was set at 10 eV with the stepping feature turned on. MS2 
collision energy was set at 100% for 70 % of the time, and 200% for the remaining 30%. Dynamic 
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exclusion was turned on, with an exclusion after 3 spectra per precursor ion for a duration of 60 s. 
Spectra corresponding to the same precursor ion were reconsidered for analysis if the new spectral 
intensity was more than 2.5 times the previous intensity.  
Top speed data-dependent precursor ion selection was used for all of the three 
fragmentation modes on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific) 
with a cycle time of 3 s. The parent ions were scanned with an Orbitrap resolution of 120K and an 
automatic gain control (AGC) target of 200,000. Dynamic exclusion was turned on with the 
following settings: exclusion time = 60 s; mass tolerance = +/- 10 ppm; repeat count = 3. For 
Orbitrap (OT) detection, the parent ions were scanned in the range of 300–1500 m/z, the fragment 
ions were scanned with an Orbitrap resolution of 30K, maximum injection time of 60 ms, and 
AGC target of 50,000. Precursor ions with a charge ranging from +2 to +7 were considered. A 
higher range of charge states has been used for OT as a majority of peptides analyzed via 
electrospray ionization (ESI)-OT-MS are multiply charged. Additionally, several contaminant ions 
present in the sample are usually singly charged. So, to avoid the background noise caused by 
those contaminants, a charge state of +2 to +7 was chosen. However, in ESI-QTOF-MS, a 
significant number of singly charged peptides are present; hence, a lower charge state range of +1 
to +4 was chosen. A normalized collision energy value of 35% was used for the HCD 
fragmentation. For the ion trap (IT) detection, a maximum MS2 injection time of 35 ms and an 
AGC target of 10,000 was chosen. A normalized collision energy of 35% was used for both CID 





4.3.5 MS2 data characteristics  
The average numbers of the MS1 and MS2 spectra acquired by each of the instrumental 
platforms are as follows. For MS1 spectra—HCD-OT: 6396.67 (+/- 123.86 SD); CID-IT: 10528.67 
(+/- 25.65 SD); HCD-IT: 12535.67 (+/- 258.12 SD), and QTOF-CID: 6041.67 (+/- 704.92 SD). 
For MS2 spectra—HCD-OT: 55531 (+/- 239.22 SD); CID-IT: 77507.33 (+/- 225.63 SD); HCD-
IT: 89481.33 (+/- 1344.339 SD), and QTOF-CID: 41332.67 (+/- 1466.04 SD). The OT data were 
acquired in .raw format and the QTOF data in .d format. 
4.3.6 Bioinformatic peptide sequencing and identification, and post-search filtering criteria  
The raw spectra from the QTOF instrument were converted into. mzxml format and loaded 
into the de novo-based peptide identification search engine, PEAKS Studio (Version 8.0, 
Bioinformatics solution Inc., Canada). The .raw spectra from the OT were directly loaded into 
PEAKS. The A. californica database (total entries 434) was used individually and merged with the 
H. sapiens database (total entries 139,331) from UniProt 19 (https://www.uniprot.org/) for all of 
the searches. The search parameters were consistent across all four datasets from the four 
instrumental methods tested, and included no enzymatic digestion and variable PTMs of up to 3 
per peptide: acetylation (K- and N-terminus), amidation, phosphorylation (S,T, and Y), half-
disulfide bond per cysteine residue, pyroglutamination from E and Q, and Met oxidation. For the 
QTOF detection method, a precursor ion tolerance of 50 ppm and fragment ion tolerance of 0.1 
Da were used. Different precursor and fragment ion tolerance settings were used to search the data 
obtained by the Tribrid instrument because of the difference in mechanisms behind the ion 
acquisition for its different mass analyzers. OT is a high-resolution detector with greater mass 
accuracy, whereas IT can analyze ions at a much faster rate but with lower mass accuracy. To 
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accommodate the differences in the operational mechanism of these two analyzers, separate 
precursor and product ion filtering criteria were used for different analyzer combinations when 
searching the database with the respective data: 20 ppm precursor ion tolerance with 0.02 Da 
fragment ion tolerance for HCD-OT, and 20 ppm precursor ion tolerance with 0.3 Da fragment ion 
tolerance for CID-IT and HCD-IT. Alternate search criteria with a 0.1 Da mass tolerance for both 
the OT and IT detectors were used but resulted in fewer chemically unique peptide hits. A filtering 
criterion of a 5% peptide-spectrum match (PSM) FDR was used for calculating the total number 
of peptide, neuropeptide and precursor protein identifications. Additionally, filtering criteria with 
four different FDR percentages viz., 0.1%, 0.5%, 1%, and 2%, and database searches with 
amidation as the only allowable variable PTM, were performed to evaluate the effect of these 
parameters on the FDR trends using the different instrumental methods. 
Search engines, the software tools that are used to predict the peptide sequence from an 
MS2 spectrum, are broadly classified into two categories: de novo sequencing and database 
searches. De novo sequencing algorithms predict the peptide sequences purely based on the pattern 
of MS2 fragmentation, whereas the database search algorithms try to match the generated MS2 
spectrum to a sequence within the database. Modern search engines like PEAKS-DB use a hybrid 
approach that implements both de novo sequencing and database search strategies to improve the 
accuracy and sensitivity of peptide identifications, as described by Zhang et al. 28. Briefly, PEAKS-
DB first performs a de novo sequencing for each input spectrum followed by a peptide shortlisting. 
The shortlisted peptides are then assigned a score based on the match between a database sequence 
and an experimentally acquired MS2 spectrum, and referred to as a PSM. A peptide is scored higher 
if there are multiple high-quality PSMs, all mapping to the same sequence in the database, and 
scored lower if there is just one low-quality PSM that maps to the sequence. Several factors 
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influence the scoring of peptides during the database search with MS2 data: peptide length, search 
space, number of fragment ions in the spectrum, and quality of the spectrum due to the mass 
accuracy of precursor and fragment ions, resolution, and signal-to-noise ratio. Peptide scores 
reported by a database search engine, however, ignore the biological feasibility of a peptide and 
calculate the FDR on an exclusively statistical basis 29.  
4.4 Results 
4.4.1 Peptide and neuropeptide identification rates  
The identification rates from data acquired using four different parameters (one for the Q-
TOF IMPACT and three for the Orbitrap Fusion) were evaluated based on bioinformatic metrics, 
including the confident identification of the total number of peptides, mature neuropeptides 
originating from known or predicted cleavage sites on the prohormone, percentage of the precursor 
protein sequence coverage by the neuropeptides, and percentage of false-positives via known PTM 
sites. For simplicity, only mono or di-basic cleavage sites on the prohormone were assessed to 
compare mature neuropeptides with potential peptide fragments from post-mortem degradation. 
The HCD-OT method resulted in significantly higher (p <0.05) numbers of peptide and 
neuropeptide identifications of 735.0 (+/- 37.6 SD), 238.3 (+/- 7.2 SD), respectively, compared to 
the HCD-IT and CID-QTOF. With the HCD-IT, 501.7 (+/- 49.6 SD) peptides and 136.7 (+/- 13.1 
SD) neuropeptides were identified, whereas the CID-QTOF dataset generated 373.7 (+/- 91.7 SD) 
and 93.7 (+/- 27.5 SD) peptides and neuropeptides, respectively. Using CID-IT, 666.3 (+/- 42.9 




4.4.2 Prohormone identification rates from the A. californica protein database 
Proteins with at least two chemically unique peptides were considered as a hit for the 
peptide precursor protein identification (Figure 4.3). Using these criteria, the three Orbitrap 
methods—HCD-OT, CID-IT, HCD-IT—allowed identification of 61 (+/- 3.6 SD), 52.7 (+/- 7.1 
SD), and 56 (+/- 7.2 SD) proteins, respectively; CID-QTOF resulted in identification of 25 proteins 
(+/- 3 SD). Additionally, precursor protein sequence coverage by the individually identified 
peptides was evaluated in our study on an example of one unique prohormone, the egg-laying 
hormone (ELH). The ELH prohormone is highly expressed in the abdominal ganglion. Unlike 
many other prohormones detected in abdominal ganglion extracts, ELH encodes about 20 mature 
peptides, which have been previously characterized by MS 30-32. We looked at the peptides with 
endogenous mono/dibasic cleavage sites to differentiate between the full-length mature 
neuropeptides from degradation products and sequentially cleaved ladder peptide sequences. All 
three methods employing the OT mass analyzer showed a consistent 21–22% neuropeptide 
detection among the ELH-mapped peptides, whereas only 15.5% of the mapped peptides turned 
out to be endogenously cleaved neuropeptides in the Q-TOF dataset. 
4.4.3 Evaluating MS2 spectral quality via searching against a mixed species database  
To evaluate the quality of the spectral data acquired by the different platforms, we 
constructed a mixed species database consisting of the A. californica proteins and predominantly 
irrelevant proteins from H. sapiens by appending both the proteomes. This inflated database 
approach of results validation should help illuminate the quality differences among MS2 datasets 
from different platforms. Because of the increased number of high-scoring random hits from an 
inflated decoy database 33, datasets of lower quality are expected to have a greater drop in the 
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number of confident peptide identifications. As expected, a database size-dependent decrease in 
peptide identification rates was consistently observed across all of the platforms (Figure 4.4). The 
HCD-IT method showed the largest decrease in the number of confident peptide identifications, 
which dropped 84%, from 501.7 (+/- 49.6 SD) to 81.3 (+/- 7.1 SD) when using the multi-species 
database. Other tested instrumental methods performed similarly, with a 63–67% drop in the 
peptide identification rate. In particular, with the CID-QTOF method, the average total peptide 
identifications were reduced from 373.7 (+/- 91.7 SD) to 126.3 (+/- 43.9 SD); the CID-IT and 
HCD-OT methods resulted in identification of 251.0 (+/- 16.5 SD) and 323.3 (+/- 11.0 SD) Aplysia 
peptides, respectively, from the mixed-species database. 
4.4.4 Peptide FDR estimation via identification of incorrectly assigned amidation  
Here we assessed the biological feasibility of peptide structures deduced by PEAKS to 
evaluate the peptide level FDR. One advantage of using known enzymatic processing steps is that 
one can determine impossible PTMs. For example, amidation on residues that are not followed by 
a C-terminal glycine serves as a reliable way to check false-positives hits in automatic sequencing. 
Here we computed the percentage and an absolute number of such falsely identified peptides for 
five PSM-level FDR filters applied to PEAKS DB search results, i.e., 0.1%, 0.5%, 1%, 2%, and 
5%. For a fixed search engine PSM level FDR cut-off of 5%, the average percentages of incorrectly 
identified amidated peptides were 29.3 (+/- 2.3 SD), 35.6 (+/- 7.4 SD), 36.3 (+/- 3.3 SD), and 51.0 
(+/- 6.6 SD) for the HCD-OT, CID-IT, HCD-IT and CID-QTOF methods, respectively (Figure 
4.5). These percentages correspond to the peptide-level FDR values. Even for a strict search engine 
cutoff of 0.1% PSM FDR, the percentage of falsely identified amidated peptides ranged from 9.9 
% (+/- 0.9 SD) using HCD-IT to 18.5 % (+/- 18.0 SD) using CID-QTOF, representing almost an 
order of magnitude range in the corresponding peptide-level FDR values reported by the search 
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engine. Additionally, we noticed that higher the performance of the MS instrument in terms of 
mass resolution (OT and TOF analyzers), the greater the error in the FDR, as observed versus 
calculated compared to low resolution analyzers (IT). This trend is more apparent for the lower 
PSM FDR cutoff values (0.1%, 0.5%, and 1%). 
4.4.5 Occurrence of falsely amidated peptides among the technical replicates  
The number of falsely amidated peptides among all peptide sequences with amidation that 
were identified in all three technical replicates was also determined for each of the studied 
methods. The false amidation results are as follows: CID-QTOF, 2 out of 15 total amidated 
peptides; HCD-OT, 8 out of 89; CID-IT, 6 out of 60; and HCD-IT, 1 out of 40. 
4.4.6 Influence of search spaces on PSM assignment  
An additional search with amidation as the only allowable variable PTM was performed to 
evaluate the effect of a reduced search space on PTM assignment. In this case, no significant 
difference was observed in the average number of peptides with false amidation relative to typical 
search space with seven other PTMs. Again, the five different PSM FDR filters were tested (0.1%, 
0.5%, 1%, 2%, and 5%), and false amidation occurrence significantly increased the true FDR 
relative to the search engine reported value. 
4.4.7 Fragmentation efficiency as a likely basis for false amidation identification in 
sequencing tools  
The quality of an MS2 spectrum plays a crucial role in peptide sequence determination 
using bioinformatics tools. PEAKS only reports a candidate peptide sequence with the best match 
to a spectrum as a highest score hit. The match is determined by mass accuracy and the number of 
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assigned fragment ions. For example, peptide R.GIFTQSAYGSYPRV(a).G (-10LogP score of 
98.98) is C-terminally amidated with a glycine residue following valine (Figure 4.6). This peptide 
has a complete list of high-intensity b and y fragment ions that facilitate a confident and accurate 
estimation of the peptide sequence. In contrast, L.FGLTISDMGCAITLF(a).W (-10LogP score of 
20.07) is one of the false PTM identifications where the C-terminal phenylalanine is followed by 
a tryptophan and not a glycine. The MS2 fragmentation pattern (Figure 4.7) and distribution of b 
and y ions for this peptide reveal that the ions in the m/z range of 800–1800 are mostly absent, so 
essentially the sequence has been determined based on fewer fragment ions. Though poor 
fragmentation and insufficient confirmation of proposed sequence via experimental fragment ions 
are the reasons for most false amidation assignments, the converse, however, is not true. The 
peptide R. GGSLDALRSGHQVPMLRA(a).GR (-10LogP score of 19.66) has a similar length, 
fragmentation efficiency, ion coverage, and -10LogP score (Figure 4.8) as the falsely amidated 
peptide L.FGLTISDMGCAITLF(a).W. However, this is most likely a low-abundant true positive 
as it has basic cleavage sites on both of the termini, and the amidation occurs on the residue 
preceded by glycine. 
4.5 Discussion 
Automated database searches are an integral tool for high-throughput discovery and 
characterization of neuropeptides from MS2 data; however, a growing body of research has drawn 
attention to unrealistic FDRs reported by the majority of database search engines for MS2 data 
interpretation. Solutions to address this issue range from improved algorithms and their 
combinatorial strategies, to the possibility of biological validation of automatically generated 
peptide identifications 34-38. Here we investigated how spectral characteristics from different MS 
platforms work with a commercial bioinformatics package for effective peptide identification, and 
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show that screening for C-terminus amidation, which requires a following glycine, allows one 
category of false-positive identifications to be determined. The screening approach was found 
effective for datasets obtained with different mass analyzers and molecular dissociation methods.  
The details of the specific MS platform used influence automatic peptide identification outcomes. 
As evident from the average total number of unique peptide sequences obtained, HCD-OT resulted 
in a significantly higher number of total peptide identifications compared to HCD-IT and CID-
QTOF. Additionally, datasets acquired with the OT- and IT-based methods contained 20–50% 
more MS2 spectra compared to the TOF dataset. Although the average total number of unique 
peptides identified by CID-IT was lower than HCD-OT, the difference was not significant (p 
>0.05). The number of neuropeptide identifications also followed the same trend as the number of 
total peptides identified. Identifying the mature neuropeptides aids in distinguishing between the 
endogenous peptides and the peptides produced as an artifact of sampling, measurement, or 
sequencing errors. This difference distinguishes the redundant peptide forms that are usually the 
sequential degradation products of a mature full-length peptide. In most cases, the full-length 
mature neuropeptides are the biologically active compounds that bind to specific receptors and 
modulate various physiological functions. Loss or substitution of even a single amino acid residue 
in a peptide sequence may compromise G-protein receptor coupling 39.  
Although a search engine estimates PSM-level FDRs from a statistical viewpoint, a more 
practical peptide-level FDR is appropriate for studies that rely on peptide identification results. 
Typically, multiple correct PSMs for each sequence tag could be produced from an MS2 dataset, 
and the best scoring PSM is reported by the search engine used as a representative of the peptide. 
In contrast, the false identifications are usually supported by a single PSM to a low quality MS2 
spectrum. This results in a significant difference between a search engine-reported PSM-level FDR 
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value and the peptide-level FDR. Although few search engines evaluate the peptide-level FDR, 
they do report the empirical FDR, which makes them prone to biases in the datasets. Jeong et al. 
27 evaluated both factual and empirical peptide-level FDRs, but their reported factual peptide-level 
FDRs still depended on the results from the target-decoy approach, and may have introduced bias. 
Individual evaluation of mass spectra to confirm the identity of the PSMs is a plausible approach 
to address the above issue, but doing a manual inspection of all spectra in a typical MS experiment 
containing several thousand spectra is time consuming. Moreover, oftentimes it is not possible to 
determine whether a PSM is a true positive or a false positive.  
Taking a different approach, we took advantage of the fact that C-terminal amidation 
cannot occur without the loss of glycine as a glyoxylate ion. In mammals, amidated peptides play 
roles in neuropeptide signaling pathways by mediating water balance (antidiuretic hormone), 
pregnancy and lactation in females (oxytocin), and positive regulation of cytosolic calcium ion 
concentration, among many other functions 40-42. The results from the current study indicate that 
for any given PSM-level FDR cutoff, the search engine-estimated FDR percentage of peptides is 
always lower compared to the percentage of false positives estimated via evaluation of false 
amidation. While high quality mass spectra should minimize the number of false positives from a 
database search, our data suggest that the issue may be related to the method used to characterize 
the FDR because the percentage errors in FDRs are nearly as high in the platform with the best 
MS figures of merit, and are larger for more strict FDR values. Also, the fact that we observed a 
greater error in observed versus calculated peptide FDRs for higher resolution MS instruments 
suggests that the problem could lie in the informatics routines used.  
However, there are limitations to using amidated peptides at a constant FDR filter as a 
benchmark to evaluate the false positives. Firstly, they represent only 15–20% of the total peptide 
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identifications; hence, the sample set is smaller. Secondly, amidation is known to occur only in the 
secretory pathway in acidified vesicles, and so is not applicable to datasets outside of secretory 
products. Lastly, though a constant FDR filter ensures that the ratio of decoy PSMs to total PSMs 
remains consistent across all the platforms as calculated by the search engine used, the actual ratio 
could vary from platform to platform, depending on the spectral quality and the database used to 
search. Since there is no real way to verify the identity of all peptides, benchmarking amidated 
peptides provides a fairly simple and reasonably accurate way to estimate false positives, despite 
the caveats mentioned above.  
It is important to note that the MS2 fragmentation pattern of a precursor ion has a significant 
impact on the peptide identifications. By manually inspecting the data, we found that false 
identifications usually associate with low fragmentation spectrum quality and/or disparate peptide 
sequence coverage by assigned fragment ions. PEAKS identifies the maximum discriminating 
fragment ions, and attributes the amidation site to the last residue, if subtracting 0.98 Da leads to 
a sequence with a higher number of fragment ion matches to the experimental spectrum, which 
results in the false identification. In contrast, with an efficient fragmentation spectrum, the correct 
sequence is easily fitted to the spectrum, which leads to a true identification with an amidation 
followed by a C-terminal glycine. Although there are falsely amidated peptides common to all the 
three replicates for all platforms, the ratio of the number of false identifications over total 
identifications among the peptides common to all the three replicates is much lower than the same 
ratio for individual technical replicates. These low percentages of false positives that are common 
to the three technical replicates, for a given experimental platform, suggest that the PSMs that 
result in factual false positives do not consistently occur in different technical replicates, i.e., the 
wrongly assigned m/z are not detected in all of the replicates. We observe similar peptide FDR 
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values when using a reduced search space with amidation as the only allowable PTM, suggesting 
that the percentage of peptides identified to be incorrectly amidated is not likely due to the search 
parameters, such as search space and number of PTMs chosen, but is more dependent on the quality 
of the MS2 spectra acquired. Oftentimes spectra with poor/incomplete lower mass ions are 
assigned to a false amidation. 
Searches using the multispecies database of H. sapiens + A. californica understandably 
resulted in significant decreases in the total peptide identifications across all platforms. This can 
be attributed to the well-known fact that fewer PSMs would cross the search engine threshold 
when searched against a larger database compared to a more compact database 27, 43. The smallest 
decrease (56% compared to the Aplysia-only database) in unique peptide identifications in the 
mixed-species database was noticed with the method employing HCD fragmentation with the OT 
analyzer. HCD-OT offers high-resolution ion detection, no low-mass cutoff, and increased parent 
ion fragmentation, which leads to an overall good MS2 spectral quality. Because of these reasons, 
around half of the peptides from the A. californica-only database were also confidently matched 
to a protein in the A. californica database, despite the presence of an overwhelmingly large number 
of proteins from H. sapiens in the mixed-species database. In contrast, HCD-IT resulted in the 
largest percentage decrease in peptide identifications (84% decrease in peptide identifications 
compared to the results obtained from the Aplysia-only database). After adding the human proteins, 
the increased size of the database resulted in many PSMs not crossing a set threshold, resulting in 
the decrease in identifications. Hence, though HCD-IT has an edge over other methods in terms of 
its high speed and fragmentation efficiency, the benefits may be offset when searching against a 
large protein database, which is often the case when using models with unsequenced or poorly 













Fig. 4.1: Schematic of post-translational prohormone processing. (A) The prohormone is 
acted upon by several endopeptidases, followed by other enzymes, to form various PTMs, 
leading to the full-length neuropeptide hormones. (B) Artifacts resulting from additional 












Fig. 4.2: Average number of unique peptide and neuropeptide sequences identified 
over n = 3 technical replicates for four different instrumental methods, where 
neuropeptides are defined as peptides derived from prohormones. Error bars 
represent the standard deviation. The entire list of peptides and proteins is included 












Fig. 4.3: Average number of neuropeptide precursor proteins identified 
over n = 3 technical replicates for four different instrumental methods. 











Fig. 4.4: Average number of peptides identified from n = 3 technical 
replicates for four different instrumental methods using two different 
databases: exclusively Aplysia californica (target, A.C.) and mixed 
species with precursor proteins from (A.C) + Homo sapiens (H.S.). *p 
<0.05, **p <0.01. For the peptides from the A.C. + H.S. database, all 
pairwise comparisons, except HCD-IT and QTOF-CID, are 






Fig. 4.5: Comparison of the search engine-reported peptide FDR percentages to experimentally 
determined percentages for the occurrence of false positives using all of the four tested 
platforms. The x-axis corresponds to the constant PSM FDR threshold cutoff used to filter the 
results from the PEAKS search. The y-axis corresponds to the peptide level FDR percentage 
estimated by the search engine and experimentally determined value via evaluation of incorrect 
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The habenular nuclei are small structures symmetrically located above the posterior end of 
the thalamus (part of the epithalamus) functionally linking the forebrain and the midbrain. They 
are phylogenetically conserved in vertebrates 1. The habenula nucleus has two substructures, the 
medial and lateral subnuclei, which interconnect with different brain regions 2. The habenula had 
not attracted significant attention until the discovery of its involvement in the reward system 3-6. 
To date, the habenula has been found to play important roles in a wide range of physiological 
processes, including sleep regulation, reward-based decision-making, avoidance and mood 
behaviors, and drug addiction, particularly tobacco dependence 7-10. An important step in 
understanding the contribution of the habenula to these biological events and behaviors is to 
elucidate the cell-to-cell signaling molecules, including neuropeptides, present in this brain region. 
Additionally, there are orphan G-protein coupled receptors (GPCRs) densely or exclusively 
expressed in the habenula 11-12; characterizing the peptide complement in the habenula may help 
to uncover the endogenous ligands for these GPCRs.  
Neuropeptides are important cell-to-cell signaling molecules involved in the coordination 
of behavioral, cognitive, and homeostatic events involving various physiological functions, such 
as food intake, pain sensation, circadian rhythms, and tissue regeneration, as well as many 
pathophysiological processes such as drug addiction 13-17. These signaling peptides are produced 
by post-translational enzymatic processing of large precursor proteins called prohormones at 
conventional cleavage sites, which include mono/di-basic amino acid motifs. To modulate the 
biological functionality of peptides, many neuropeptides also undergo post-translational 
modifications (PTMs) 18-19, resulting in the formation of chemically unique peptides possessing 
the same sequence of amino acids.  
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The development of modern mass spectrometry (MS) techniques, aided by improvements 
in sample preparation methods, have changed the way peptide detection, identification, and 
quantitation are performed, allowing characterization of a fairly complete set of neuropeptides 
present in a biological structure 20-24. In the past decade, hundreds of neuropeptides have been 
discovered and identified from a range of animals using matrix-assisted laser desorption/ionization 
(MALDI) MS and electrospray ionization (ESI) MS 15, 17, 25-28.  
In the current study, we implemented a custom MS method to study the occurrence of 
sulfated neuropeptides in the habenular region. Tyrosine (Tyr)-sulfation is a well-known PTM that 
is involved specifically in modulating protein-protein and ligand-receptor interactions 29-34. 
Though sulfation as a modification of proteins was identified in the early 1950s 35, determination 
of the exact site of Tyr-sulfation using MS is still a challenging task for several reasons. First, 
sulfation increases the mass of the modified peptide by almost the same amount (+79.9568 Da) as 
phosphorylation (+79.9663 Da). Moreover, both PTMs can occur on Tyr. Secondly, sulfation is a 
labile PTM where the SO3 group falls off, even with soft ionization techniques such as ESI. Finally, 
even if sulfation remains after ESI, it does not survive during classic collision-induced dissociation 
(CID), making it difficult to determine the site of the modification. To overcome these difficulties, 
we used a custom approach utilizing beam-type CID (high-energy C-trap dissociation, or HCD) 
and electron transfer HCD (EThcD) dissociation techniques. The obtained data were manually 
deconvoluted, revealing neutral loss signals of the parent ion corresponding to a mass difference 
of 80 Da. Using this approach, we confidently localized four novel sites of modification for 
sulfation on the secretogranin I (SCG1) prohormone.  
The data presented here is the first comprehensive study for the localization of sulfated 
neuropeptides in the vertebrate habenula. This information on the neuropeptide content and PTMs 
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of these molecules in the habenular nuclei can be used as a basis for better understanding of the 
roles of cell-to-cell signaling molecules in different biological processes.  
5.3 Materials and methods 
5.3.1 Materials  
The solvents used were of LC–MS grade and obtained from Thermo Fisher Scientific 
(Waltham, MA), except for triethylamine, acetone, and hydrochloric acid, which were obtained 
from Sigma-Aldrich (St. Louis, MA).  
5.3.2 Habenula isolation and stabilization 
Male Sprague Dawley rats, 8–12 weeks old, were euthanized by decapitation in compliance 
with animal use protocols approved by the University of Illinois Institutional Animal Care and Use 
Committee and in accordance with all state and federal regulations. Targeted brain areas were 
identified according to the Paxinos and Watson rat brain atlas 36, surgically isolated, and stabilized 
as outlined below. Samples from the identical habenula regions were pooled together for analysis 
with individual techniques. For characterization of the sulfated peptides via LC–Orbitrap MS, 
medial and lateral habenula regions from 3 rats were isolated and subjected to heat stabilization 
by the Denator Stabilizor (ST1) 37 and pooled into one sample.   
5.3.3 Extraction of endogenous peptides 
The isolated habenula tissues were stabilized by the ST1 or hot water, followed by a three-
stage peptide extraction process, as described in our previous work.28 Briefly, habenula tissues 
were homogenized in 200 µL of ice cold water and incubated on ice for 1 h. Supernatants were 
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saved in a new microcentrifuge tube after centrifugation at 14,000 × g for 10 min. The tissue pellets 
were subjected to two more stages of peptide extraction with acidified acetone (acetone:H2O:HCl 
40:6:1) and 0.25% acetic acid solution, respectively, performed in a similar manner. The 
supernatants collected during these three extraction steps were combined.  
The volume of combined supernatant sample was reduced to about 20 µL using a vacuum 
pre-concentrator device (GeneVac, UK) leading to preferential HCl and acetone removal. 
Concentrated samples were desalted with a C18 spin column (Thermo Fisher Scientific). Each 
eluent fraction was collected, dried using a vacuum pre-concentrator, and stored in a –20 °C freezer 
until LC–MS analysis. 
5.3.4 LC–Orbitrap MS for characterization of sulfation PTM 
The peptide extracts were analyzed using the Orbitrap Fusion Lumos Tribrid mass 
spectrometer (Thermo Fisher Scientific) coupled to the Dionex UltiMate 3000 UPLC system 
(Thermo Fisher Scientific) located at UW. A binary solvent system composed of H2O containing 
0.1% FA (solvent A) and ACN containing 0.1% FA (solvent B) was used for all analyses. Peptides 
were loaded and separated on a 75 μm × 15 cm column, fabricated in the lab and packed with 1.7 
μm, 150 Å, BEH C18 material (part no. 186004661, Waters, Milford, MA). Samples were loaded 
with 3% solvent B, and solvent B was linearly ramped to 30% in 102 min, and ramped to 75% in 
another 20 min at a 300 nL/min flow rate. Data were acquired in data-dependent mode using the 
Orbitrap mass spectrometer with EThcD and high-energy C-trap dissociation. The precursor ions 
in the range of 300–1500 m/z were scanned with an AGC target set to 2e+5 and an Orbitrap 
resolution of 60,000. The fragment ion analysis for the precursors was divided into five different 
scan events based on the charge state of the precursor ion. Scan event 1: intensity>1e+4; scan event 
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2: intensity>1e+4 and charge state 2; scan event 3: intensity>1e+4 and charge states 3–4; scan 
event 4: intensity>1e+4 and charge state 5; scan event 5: intensity>1e+5 and charge states 6–8. 
Scan event 1 analyzed all ions, whereas the other events only looked at specific charge states. The 
electron transfer dissociation reaction times were chosen appropriately for scan events 2–5, 
depending on the charge state. All of the scan events were performed with an Orbitrap resolution 
of 15,000 and AGC target value of 5e+4. 
5.3.5 Sulfated peptide identification 
The .raw files from the HCD + EThcD method for the sulfated peptide analysis were 
processed with Byonic software (version 2.0, Protein Metrics, San Carlos, CA). Data were 
searched against a rat neuropeptide database (http://isyslab.info/NeuroPep/). A precursor tolerance 
of 10 ppm and a fragment mass tolerance of 20 ppm were allowed. Acetylation (N-term), oxidation 
(M), pyro-glu from E, and pyro-glu from Q were set as rare dynamic modifications. Common 
dynamic modifications consisted of phosphorylation (STY) and amidation (C-term). The mass 
spectra of the peptides identified to be sulfated were manually analyzed for the presence of a 
neutral loss of SO3 that corresponds to a mass difference of 80 Da 
38-39 (Figure 5.2). 
5.4 Results and discussion 
The habenular nuclei encompass two small regions symmetrically located in the brain 
hemispheres; these nuclei have important roles in a range of behavioral phenomena, including drug 
addiction and depression 1, 9, 40. Neuropeptides are important cell-to-cell signaling molecules 
involved in these phenomena 41-43. While immunohistochemical methods and in situ hybridization 
have been used to study the distribution of selected neuropeptides or their mRNAs within the 
habenular nuclei 44-47, it appears surprising that an inventory of the endogenous neuropeptide 
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molecules present in the structure is not available. Here, we employed a combination of high-
resolution MS platforms to explore the neuropeptidome of the lateral and medial habenula in rat. 
Evaluation of the morphology, connectivity to other brain regions, and biochemistry of the 
habenula nuclei suggests that the habenula is comprised of distinct lateral and medial subnuclei, 
each of which can be further divided into several smaller subnuclear regions 48. Difficulties in the 
observation, isolation, and LC–MS analysis of these smaller subnuclei restricted our investigation 
to the lateral and medial habenula nuclei.  
Figure 1 shows the workflow of the multifaceted mass spectrometric approach used in this 
study. The current chapter specifically deals with the characterization of sulfated PTMs on 
neuropeptides derived from the habenular nuclei. This is a part of the larger neuropeptidomics 
study from our group where we characterized the entire neuropeptide complement of the rodent 
habenular nuclei. The experiments performed to identify the sites of sulfation revealed the location 
of five Tyr residues with O-sulfation. All of the five locations correspond to the prohormone 
SCG1. One of them (SCG1 [339]) has been previously reported in rats 49, whereas the other four 
are novel PTM sites of sulfation (SCG1 [330], [466], [469] and [501]). SCG1 [469] is predicted to 
be a sulfotyrosine by homology with a previously reported sulfation site in a bovine model 50. 
While secretogranins are a class of secretory proteins that have been previously shown to be 
sulfated 51, only one site of sulfation had been previously confirmed in the rat SCG1 prohormone 
49. Moreover, all of the identified peptides (Table 5.1) are either full-length forms or smaller 
fragments of two parent peptides (SCG1 [324-343] and SCG1 [454-508]), both with mono/di-
basic amino acid cleavage sites. Sulfation is associated with the secretory pathway and the 
modification is known to occur in the trans-Golgi network. Modified Tyr residues have been 
shown to modulate ligand-receptor interaction in several previous studies 32-34, 52. The important 
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role of sulfotyrosine in the regulation of ligand-receptor interactions, combined with the mono/di-
basic cleavage sites of the corresponding peptides containing this modification, make them 
interesting candidates for further evaluation of biological activity.  
5.5 Conclusions 
Habenular nuclei are morphologically, chemically, and functionally complex brain 
structures. Our peptidomic analyses utilized high-mass resolution MS-based and bioinformatics 
approaches to detect and identify 4 novel sites of sulfation on neuropeptides characterized from 
the rat medial and lateral habenula regions. The new compendium of habenular-expressed 
neuropeptides and their novel sites of sulfation PTMs adds critical details into overall picture of 
this structure’s functional and structural biochemistry. The habenular nuclei receive inputs from 
multiple brain regions and act as a bridge between the forebrain and midbrain. The neuropeptides 
identified in our study may originate from within the habenula or they may be from cells outside 
of the habenula and transported into the habenula. Due to the subtle and at times redundant effects 
of individual peptides and the high plasticity of the evaluated systems,  the novel peptides detected 
here have yet to be linked to function. We expect our results to be useful in identifying endogenous 
ligands for the habenular nuclei orphan GPCRs11-12 that may be targets for the development of 











Fig. 5.1: Workflow of the MS-based neuropeptidomic analyses of the rat habenular nuclei. 
Symmetrical habenular nuclei were isolated from the left and right brain hemispheres and 
characterized in three ways: (1) The medial or lateral habenula was analyzed with LC–ESI-
Orbitrap MS and a PEAKS search against a rat proteome database (untargeted analysis), and a rat 
prohormone database (targeted analysis). (2) The medial or lateral habenula analyte extracts were 
first fractionated during C18 solid phase extraction, then analyzed with ESI-FT-ICR MS. (3) 
Analytes extracted from the entire habenula were fractionated with capLC and analyzed by 
MALDI-FT-ICR MS. (4) The entire habenula extracts were analyzed using specific settings for 
characterization of sulfated peptides on the LC–ESI-Orbitrap mass spectrometer. The resultant raw 
spectra were searched against a rat prohormone database using Byonic 2.0. 
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Table 5.1 Sulfated peptides identified in the medial and lateral habenula identified using Byonic 

































Y[+80] 833.6565 SCG1 
R.GHHLAHYRAS[+79.957]EEEPDY[+79.957]GEE.L 
S[+80], 
Y[+80] 795.9617 SCG1 
R.GHHLAHYRASEEEPDY[+79.957]GEE.L Y[+80] 769.3069 SCG1 
R.GHHLAHYRASEEEPDY[+79.957]GEE.L Y[+80] 577.2299 SCG1 
R.GHHLAHYRASEEEPDY[+79.957]GEEL.R Y[+80] 605.5017 SCG1 


























































R.GHHLAHYRASEEEPDY[+79.957]GEE.L Y[+80] 769.3059 SCG1 
R.GHHLAHYRASEEEPDY[+79.957]GEE.L Y[+80] 577.2318 SCG1 
R.GHHLAHYRASEEEPDY[+79.957]GEEL.R Y[+80] 807.0009 SCG1 
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Machine learning-based tools for classification of peptide mass spectra 
 
6.1 Notes and acknowledgments 
This chapter introduces machine learning (ML) based tools that can be used to differentiate peptide 
spectrum matches from the non-peptide spectrum matches from the raw data acquired in a typical 
LC-MS based peptidomics experiment. My role in the project includes the conception of the idea, 
data acquisition, data processing, ML model building and interpretation of the results. Yuxuan 
(Richard) Xie helped in scripting the ML models, data visualization and data interpretation. The 
project is still ongoing and further work will be performed under the direction of Yuxuan (Richard) 
Xie. The project described is supported by Award Number P30 DA018310 from the National 












The field of proteomics and peptidomics has been truly revolutionized with the advent of 
state of the art high-speed and high-resolution mass spectrometry. Over the past two decades, 
advances in mass analyzers such as the Orbitrap 1 and time of flight (TOF) 2 coupled with enhanced 
separation techniques, high-quality ion optics and superior bioinformatics algorithms have made 
it possible to characterize several thousand peptides from a single sample 3. The high-quality MS 
spectra generated from samples analyzed via these techniques have helped researchers understand 
the mechanistic aspects of several physiological processes, follow disease progression, test 
pharmaceutical interventions, as well as discover biomarkers 4–8. However, the superior 
performance comes at the cost of the increased size of the resulting  raw MS that consist of tens of 
thousands of spectra, the majority of which do not correspond to a peptide sequence when searched 
against a target protein database using search engines such as MASCOT 9 or PEAKS 10. Huge 
savings in terms of computational resources can be obtained if those spectra that do not contribute 
towards a peptide sequence can be identified and filtered out of the raw mass spectra before they 
are processed.  
A few researchers in the past have attempted to perform such spectral filtering. Wong et 
al. 11 have implemented a probabilistic filtering approach based on signal-to-noise ratio (SNR) by 
assigning a likelihood value for all the spectra. Purvine et al. 12 have also implemented an approach 
based on SNR where all the spectra were ranked in descending order based on their intensity and 
the ones that fell below the median value were removed. A more flexible SNR based approach was 
used by Xu et al. 13 and Ding et al. 5 where different SNR thresholds were implemented depending 
on the number of peaks within spectra and m/z range of the peaks while taking into account the 
presence of water and ammonia loss in observed ions. However, these methods performed the 
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spectral filtering based on a set/fixed threshold value. While Flikaa et al. 14 proposed a machine 
learning based algorithm, it was targeted towards facilitating manual inspection of the spectra and 
dealt with raw MS files with only a few thousand spectra. Our goal is to enhance these approaches 
by creating ML algorithms that can be scaled up to perform automatic classification on >100 000 
spectra. 
The meteoric rise in computational power over the last decade has led to the advent of 
artificial neural networks (NN) in multiple facets of scientific research. NNs are abstract 
mathematical functions that can learn the complex relations between several million data points. 
NN based models have been successfully implemented to solve several problems in the fields of 
computer vision, speech recognition, supercomputing and natural language processing. Here, we 
propose two machine learning (ML) based spectral filtering algorithms: (1) ResNet- A type of 
convolutional neural network (CNN) based classification model that is extensively used for image 
classification 15 and (2) XGBoost: An ensemble supervised learning algorithm that iteratively 
combines several weak classifiers into a single strong one 16. These two models are trained on a 
set of >250 000 peptide mass spectra obtained from the nervous system ganglia of the marine 
mollusk Aplysia californica. Once trained, these models were then used to classify the raw MS 
spectra from an Aplysia ganglion that was not included in the training set (Figure 6.1 represents 
the experimental workflow). Both the above-mentioned algorithms resulted in up to a 4-fold 
reduction in the spectral count of the raw MS files which could translate to an equivalent 4-fold 





6.3 Materials and methods 
6.3.1 Chemicals 
 All chemicals and solvents were purchased from Fisher Scientific (Waltham, MA.) or 
Sigma-Aldrich Chemical Co. (St. Louis, MO) unless specified. 
6.3.2 Animals, tissue collection and peptide extraction 
Aplysia californica were obtained from the NIH/University of Miami National Resource 
for Aplysia Facility (Miami, FL), and kept at 15 0C in a tank of artificial seawater prepared from 
Instant Ocean (Aquarium Systems, Mentor, OH, USA). The animals were used within one week 
of arrival. 
6.3.3 Tissue collection and peptide extraction 
Before dissection, the animals were injected with half their body weight of 360mM MgCl2, 
after which five different ganglia (abdominal, buccal, cerebral, pleural and pedal) were isolated 
from each animal and placed in a protease solution (1% protease type IX, Sigma, 1 unit/mg, to a 
final concentration of 10 units/ml) for 1hr at 340C to unsheathe the connective tissue. Following 
the protease treatment, the ganglia were washed with artificial seawater (ASW). The five regions 
were isolated from 3 animals and pooled together. Pooled tissues were homogenized in ice-cold 
acidified acetone (acetone: water: hydrochloric acid 40:6:1) using a mechanical plastic pestle. The 
samples were centrifuged at 14,000xg and the supernatant was desalted using C18 spin column 
(Thermo, MA). The eluent was collected, dried and stored at -20 oC. Each dried sample was 




6.3.4 Liquid chromatography-Mass spectrometric analysis 
Dionex Ultimate3000 RSLC with a nano flow selector coupled to Bruker IMPACT HD 
QqTOF (Bruker Daltonics, Billerica, MA) has been used for the analysis of all the regions except 
genital ganglia. The Acclaim®  PepMap™ RSLC nanoviper column (75µm x 15 cm, C18, 2µm, 
100Å) in line with a C18 Acclaim® PepMap™ μ-Precolumn (C18, 5µm, 100 Å) has been used 
for LC-separation. The sample was loaded on the precolumn trap with loading solvent (99% water, 
1% CAN, 0.1% formic acid, 0.01% TFA) at uniform flow of 15 µL/min for 3 min, after which the 
precolumn was put in-line with the analytical column and gradient was initiated. The analytical 
flow rate was maintained at 300 nl/min with 0.1% formic acid in LC-MS grade water (solvent A) 
and 0.1% formic acid in LC-MS grade acetonitrile (solvent B) as the mobile phase. The flow 
gradient conditions were: 0-3 min, 1-1% B; 3-6 min 1-10% B; 6-90 min, 10-70% B; 90-100 min, 
70-99 % B; 100-110 min 99-1% B; 110-120 min, 1-1% B. The MS data for all the 5 regions was 
acquired on a Thermo Orbitrap Fusion tribrid mass spectrometer (ThermoFisher, MA) over a range 
of 300 to 1500 m/z in top speed data-dependent mode. Precursor ions were picked based on the 
intensity and fragmented by CID in a window of 3 sec. Dynamic exclusion was turned on and 
lasted 60 sec.  
6.3.5 Bioinformatic peptide identification 
Data from Orbitrap Fusion was directly loaded in .RAW format onto PEAKS Studio 
(version 7.5, Bioinformatics Solutions Inc., Canada). The search was performed against the 
UniProt Aplysia proteome (441 proteins) 17. The mass tolerance for precursor ion was 20 ppm. 
The remaining search parameters were: 0.1Da fragment ion tolerance, no enzymatic digestion, 
variable post-translational modifications (PTMs) up to 4 per peptide which include acetylation, 
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amidation, phosphorylation, half-disulfide bond per cysteine residue, pyroglutamination from E 
and Q, and Met oxidation. Peptide homology search using the SPIDER algorithm was performed 
on the database search results. A filtering criterion with 1.0% FDR (PSM level) was used to select 
the peptides from SPIDER search results.  
6.3.6  Parsing raw MS spectra  
The .RAW spectra from all the 5 ganglia was parsed using the pymzML python package 
18.  All the MS/MS spectra from these files were binned into a python DataFrame with 0.1 Da 
binning width. The spectra are then further annotated as true positives (labeled “1”) or true 
negatives (labeled “0”) based on whether the particular spectrum was mapped to a peptide 
sequence during the database search. The parsed spectra are split in the ratio 7:3 for training and 
validation, respectively.  
6.3.7 ML model building 
 For the XGBoost classifier, a learning rate of 0.1 was used with the number of estimators 
(learning features) of 600 and a weighted binary cross-entropy loss function. The model was 
trained for 50 iterations (epochs) to achieve convergence. For ResNet, we have implemented the 
standard architecture with following parameters: an adaptive learning rate of 1e-2 for the first 40 
epochs with reduction by a factor of 1e-1 for every 10 epochs.  A batch size of 32 spectra and a 
neural net depth of 18 (ResNet 18). A weighted binary cross-entropy loss was used to train the 
network. The python scripts for both these models can be found at the GitHub repository: 
https://github.com/kdbanapindi/ML-for-proteomics. Two metrics were used to evaluate the 
performance of the tested modes: 1) Recall: Denotes the fraction of true positives identified 
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correctly and 2) Precision: Denotes the fraction of true positive values in the total predictions 
(Figure 6.2). Both the models were tuned for high recall and precision.  
6.4 Results and discussion 
High throughput LC-MS/MS analysis has become the workhorse of protein and peptide 
characterization studies 19. The advent of mass spectrometry as the sought-after technique for 
proteomics has also resulted in the need for automated spectral pre-processing methods 20. Keeping 
this requirement in mind, we developed a spectral filtering tool based that can learn the features of 
a peptide spectra from several hundred thousand spectra previously characterized and then classify 
new spectra based on the learned features. The primary goal of our study was to retain as many 
true positives as possible (high recall) while striving for an improved precision.  
The dataset used consists of 12 000 columns (each corresponds to the 0.1 Da bin width) 
with the number of rows being equal to the total number of MS2 spectra. A 2-D visualization of 
the raw MS/MS spectra has revealed distinctive patterns in the peptide spectral matches (PSMs) 
which are absent in the rest. For example, most PSMs have an isotopic pattern characteristic of an 
organic molecule high in carbon (1.11% 13C) and nitrogen (0.36% 15N) (Figure 6.3). Moreover, 
these isotopic patterns occur at definite intervals corresponding to the amino acid(s) difference 
between different peptide fragments. These distinctive features strongly suggest that statistical 
learning algorithms such as the ones described here can be implemented for spectral classification.  
Once trained, recall was used as the primary metric to evaluate the performance of our 
models. Upon ten iterations (epochs), the XGBoost model had a training set recall of 0.93 and a 
validation set recall of 0.87. Similarly, after ten epochs, the deep neural network based ResNet 
showed a recall of 0.75 on the training set and a recall of 0.78 on the validation set. Precision, 
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which denotes the fraction of true positive values in the total predictions for both models, between 
0.3-0.4 was achieved for the reported recall (Figure 6.4 represents the precision vs. recall curve 
for both the models). Though this value seems low, the models were intentionally built to 
maximize the recall. Since the datasets are unbalanced with only a fraction of true peptide spectra 
(<10%), even a 0.3 precision (with 0.9 recall) corresponds to a ~75% reduction in the overall 
spectral count while still retaining ~90% of the true positives. Moreover, these performance 
metrics correspond to approximately 4-times faster search time, resulting in huge computational 
cost savings. Figure 6.5 represents the time savings vs. the loss of true peptide spectral matches. 
This graph however represents only the computational time required for the database search but 
not for the spectral filtering. Once the models are trained, the actual time required for the filtration 
is only a fraction of the time taken by the database search. Hence, the overall time taken is still 
significantly lesser than performing a database search on an un-filtered spectral file. 
Finally, further analysis of feature importance of the XGBoost model revealed that 
fragment ions in the range of 500-800 m/z had the highest contribution towards classifying a 
spectrum as a true positive (Figure 6.6). This corroborates with the fact that most peptide fragment 
ions do indeed fall in the same mass range. Though the current models were trained on data 
acquired from samples without any enzymatic digestion, they can easily be used to classify peptide 
sequences in a shotgun proteomics experiment (treated with enzyme such as trypsin) with minimal 
additional effort. Currently, we are extending these models to train on spectral files from the human 
proteome. Since the Aplysia proteome is a relatively smaller database with just few hundred 
characterized proteins, training the model on a larger dataset such as the human proteome would 
result in a model with learned features from a much wider array of peptides. Specifically, NN 
based models are known to perform better when trained on large amounts of data 21. Once 
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completed, this machine learning based spectral filtering tool can implemented in a standard 
proteomics workflow and can significantly speed up the peptide / protein characterization efforts 














































             
             
             
             
             
             
             
              
Fig 6.2: Machine Learning model evaluation metrics: Recall and Precision. 
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Fig 6.3: 2-D visualization of A) peptide and B) non-peptide mass spectra. 
MS/MS spectra that DOES NOT match 
to a peptide sequence 
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Quantitative assessment of global neuropeptide changes between mice models of chronic 
migraine and opioid-induced hyperalgesia 
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Migraine is among the top twenty most debilitating disorders in the world and is estimated 
to affect hundreds of million people annually 1. Despite such high prevalence and the concomitant 
societal burden of several billions of dollars annually in lost productivity and medical costs, the 
treatments available for this disorder are ineffective for a large proportion of patients 2. In a 
significant number of cases, opioid-based therapeutics, such as morphine, are prescribed to 
alleviate migraine 3-4. While opioids may provide acute relief, regular use results in 
addiction/dependence and can lead to refractory headache and contributes to the progression of 
migraine from an episodic to a chronic condition upon extended usage 3-4. In the field of pain 
management, opioid-induced hyperalgesia (OIH) has also been observed, where repeated use of 
opioids leads to several adverse effects, including an increased sensitivity and expanded area of 
pain 5. Though opioid withdrawal is seen as a potential solution to combat OIH, previous studies 
have shown around 50% relapse rate among the patients subjected to opioid withdrawal. The lack 
of proper mechanistic understanding of OIH and the chronification of migraine as a result of 
repeated opioid usage is a major roadblock to the development of effective therapies for these 
conditions. Our goal is to use animal models of these disorders to determine if alterations in 
neuropeptide dynamics within key regions that regulate nociceptive and emotional processing 
could provide insight into the underlying mechanisms governing these types of pain (Figure 7.1A). 
This knowledge will be useful in developing novel treatment procedures with reduced tendency to 
cause dependence / addiction than the existing opioid based treatments.  
 
The principal hypothesis on migraine pathogenesis is based on neuropeptide-mediated 
modulation of the trigeminovascular and other migraine-related nervous system structures. 
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Compelling evidence from previous studies on gene, transcript or receptor expression points 
towards the direct involvement of neuropeptides in the regulation of nociception, allodynia and 
chronic headaches 6-7. However, a comprehensive evaluation of the brain peptide repertoire, with 
the goal of understanding their roles in these conditions, has not been performed to date.  
Peptidomics, a direct global analysis of endogenously present peptides, is particularly illuminating 
as the approach can be used to evaluate final gene products where they act and thus, provides 
information that most other ‘omics technologies cannot. One of the primary reasons for the slow 
exploration of neuropeptide dynamics in migraine is that direct label-free approaches for the 
measurement of peptides, such as mass spectrometry (MS)-based peptidomics, lack the intrinsic 
signal amplification steps of molecular techniques, and accordingly, require more biological tissue 
per sample 8. Besides, nervous system regions involved in migraine are numerous, relatively small 
and hard to isolate reproducibly. Superseding these systematic limitations, we have measured the 
set of endogenous peptides present in detectable amounts in the following regions— trigeminal 
nucleus caudalis (TN), nucleus accumbens (NAc), dorsal horn of the lumbar spinal cord (DH), 
rostroventral medulla (RVM), trigeminal ganglia (TG), hypothalamus (H), and periaqueductal 
grey (PAG)—and identified small, overlapping, but not identical, subsets of neuropeptides 
defining migraine or OIH, and both models. For our migraine model, we used chronic intermittent 
doses of the known human migraine trigger, nitroglycerin (NTG). We 9-10, and others 11-12, have 
previously shown that this model evokes a severe basal hypersensitivity that is responsive to 
migraine preventives 9-10. For our OIH model, we administered morphine twice daily for four days, 
with an escalated dose on day 4, a protocol that produces robust OIH 13. The wealth of information 
obtained with behavioral assessment was combined with MS-powered quantitative peptidomics 
analysis of global neuropeptide changes and characterized alterations of endogenous peptides 
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derived from several prohormones, such as Pro-calcitonin gene-related peptide (Pro-CGRP), Pro-
Neuropeptide Y (Pro-NPY), Pro-Enkephalin (PENK), Pro-Opiomelanocortin (POMC) and Pro-
Tachykinin (Pro-TKN), thus laying a foundation for future functional studies and, hopefully, 
treatment. The protein pituitary adenylate cyclase-activating polypeptide (PACAP)-derived 
peptide was found to be significantly altered in both the migraine and OIH models, further 
cementing its role in the regulation of pain symptoms. Our results confirm the hypothesis that a 
shared mechanism, based on neuropeptide dysregulation, exists between these disorders.  
7.3 Materials and methods 
The study was performed twice, in two independent cohorts separated by one year (cohort 
1 and cohort 2). Both these cohorts tested the OIH (morphine) and migraine (NTG) models with 
identical treatment groups, sample collection protocols, and analysis methods. This approach was 
used to test the robustness of the approach. Significantly changed peptides and proteins in both the 
cohorts that fall below the p-value threshold (p≤0.05 for peptides and p≤0.1 for proteins) were 
considered to be truly correlated to treatment. 
7.3.1 Animal treatment  
Subjects were male C57BL6/J mice (Jackson Laboratories), between 9-12 weeks old. 
Animals were group-housed on a 12-12 light-dark cycle, and food made available ad libitum. 
Experimental procedures were approved by the University of Illinois at Chicago Office of Animal 
Care and Institutional Biosafety Committee, as per AALAC guidelines and the Animal Care 
Policies of the University of Illinois at Chicago, as well as with the European Union directive on 
the subject of animal rights. Animals were weighed daily during treatment, and no adverse effects 
of treatment were observed on body weight or visibly healthy performance 
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For behavioral experiments, animals were counterbalanced into groups following the first basal 
test for mechanical sensitivity. The experimenter was blinded to the drug condition being tested. 
Animal testing occurred in low-light conditions, between 8-15 h. To determine mechanical 
responses, the threshold for response to punctate mechanical stimuli was tested according to the 
up-and-down method. Animals were habituated to the testing boxes for 2 days prior to testing. For 
hindpaw sensitivity, the plantar surface of the animal hindpaw was tested. For cephalic testing, the 
periorbital region caudal to the eyes and near the midline was tested. In both cases, the testing 
region was stimulated with a series of eight von Frey filaments (bending force ranging from 0.008 
to 2 g). Groups were counterbalanced based on their naïve baselines (basal responses taken on day 
1). 
Injections were administered as a 10 mL/kg volume. Other drugs were dissolved in 0.9% 
saline solution, which was used as the corresponding vehicle control. For chronic migraine, mice 
were injected with NTG (10 mg/kg, American Reagents) or vehicle every other day for 9 days (5 
testing days). On test days, baseline mechanical responses were taken before drug administration 
and post-treatment responses were assessed 2 h post-drug treatment. For OIH, mice received SC 
injections of morphine or vehicle twice daily for 4 days. On days 1-3 the dose of morphine was 20 
mg/kg, and on day 4 it was 40 mg/kg. Baselines were determined before the morning injection of 
morphine/vehicle. For PACAP experiments, M65 (0.1 mg/kg, Bachem) or vehicle was 
administered SC 30 min before testing.  
7.3.2 Tissue collection  
For both models, tissue was collected 24 h following the final injection of drug or vehicle. 
Mice were anesthetized by injection of Somnasol and then perfused transcardially with ice-cold 
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physiological saline to remove the blood and preserve the integrity of live neural tissue. Brains 
were immediately removed and sliced on a cold brain matrix. Brain regions of interest were 
isolated from brain slices according to Paxinos stereotaxic coordinates using a biopsy punch of a 
suitable diameter 14; isolated samples were thermally stabilized using a Stabilizor T1 tissue 
stabilization device (Denator), transferred into microcentrifuge tubes and frozen on dry ice for the 
duration of sampling. Samples were stored at -80 °C until use. 
7.3.3 Peptide extraction  
Samples were thawed and homogenized on ice. Prior to peptide extraction, tissues from 5-
animals (cohort 1) and 3 animals (cohort 2) were pooled together to form one biological replicate. 
These pooled samples were then subjected to a three-stage peptide extraction 15. The peptide 
extracts were desalted using C18 spin columns (Thermo Fisher Scientific). Following the 
desalting, the samples were vacuum dried and stored at -20 ºC till further use. 
7.4 Mass spectrometric measurement design 
Two nanoLC-nanoESI-MS platforms were used in the study: Orbitrap Fusion Tribrid 
(Thermo Fisher Scientific) was used for peptide sequencing/identification and library construction 
from pooled aliquots of all individual samples (10%v/v), and  IMPACT HD Q-TOF (Bruker 
Daltonics) for quantitation of peptides in individual biological replicates by peak area of precursor 
ions in MS1 scans. Peptide libraries built from the first cohort samples were used as a reference to 
quantify the corresponding peak areas in MS1 spectra acquired from both 1st and 2nd cohorts, as 
described in the next section. The technical justification of our experimental design is that Orbitrap 
mass analyzers are known to be influenced by space charge effects which could potentially affect 
the quantitation results. QTOFs that do not trap ions are not prone to space charging and offer 
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advantage in quantitative application. It has also been shown that Orbitrap mass analyzers have a 
reduced intrascan dynamic range compared to TOFs16. Besides, analysis of MS1 scans in straight 
forward and robust, which was critically important with the number of samples to measure and 
quantify (7 regions x (3 biological replicates cohort one + 5 biological replicates cohort 2) x 4 
conditions = 224) 
7.4.1 LC-MS and LC-MS/MS analysis  
Each of the vacuum dried samples was reconstituted in 10 μL of water supplemented with 
0.1%(v/v) formic acid and subjected to LC-MS analysis. Briefly, for identification, the samples 
were separated on a Dionex Ultimate 3000 nanoLC system (Thermo Scientific) using a reversed-
phase C18 column (PepMap Thermo Scientific 75 μm × 15 cm, C18, 2 μm, 100 Å) with a solvent 
gradient consisting of solvent A (H2O with 0.1% formic acid (FA)) and solvent B (acetonitrile 
with 0.1% FA) at 300 nl/min. The runs lasted for 120 min. with the following gradients: 0-3 min, 
1-1% B; 3-6 min, 1-10% B; 6-90 min, 10-70% B; 90-100 min, 70-99% B; 100-110 min, 99-1% B; 
110-120 min, 1-1% B. Data was acquired using a nanoESI (electrospray ionization) source in a 
data-dependent MS/MS mode via collision-induced dissociation (CID) over an m/z range of 200-
1200 with dynamic exclusion turned on (exclusion after 2 spectra within 30 sec.). However, the 
ion is reconsidered if it elutes after 60 sec. or later. The parent ions were scanned with an Orbitrap 
resolution of 120K with an AGC target value of 200,000. Precursor ions with a charge ranging 
from +1 to +7 were considered. A normalized collision energy value of 35% was used for 
fragmentation via collision-induced dissociation. For the quantitation run, same LC system was 
hyphenated to a Q-TOF mass spectrometer via Captive Source (Bruker Daltonics), and separation 
method was exactly the same as used for  the identification experiments on an orbitrap instrument 
The data were acquired in MS (MS1) mode over a range of 290-3000 m/z with a cycle time of 3 
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sec. A fixed MS1 scan rate of 1 Hz was used. An absolute intensity threshold of 694 counts (100 
per 1000 sum) was used for spectra collection. Data are available via ProteomeXchange with 
identifier PXD013362. 
7.4.2 Peptide identification and tissue-specific peptide libraries  
The acquired .raw files from the Thermo Orbitrap Fusion were directly imported (without 
any peak filtering) into PEAKS 8.0 software (Bioinformatics Solutions Inc.) and searched against 
a mouse proteome database with 81,515 proteins that was downloaded from UniProt 17 for 
identification. The following database search parameters were used: precursor mass tolerance, 20 
ppm; fragment mass tolerance, 0.1 Da; no enzymatic cleavage; variable post-translational 
modifications (PTMs), including acetylation (K and N-terminal), amidation, phosphorylation 
(STY), half-disulfide bond (C), pyroglutamination (E and Q)and Met oxidation (M); maximum 
number of variable PTMs, 3. A FDR threshold of 1% (for peptide-spectrum matches (PSMs)) was 
used to filter the identified peptide sequences. The FDR was estimated by the PEAKS target-decoy 
approach. The list was then manually validated to remove possible false positives for quantitation. 
These include incorrect PTMs, such as c-terminal amidation, for peptides where the subsequent 
amino acid is not a glycine, caused by the statistical nature of sequence assignment by the search 
engines 18. A total of over 200 LC-MS runs were performed on seven different regions in two 
independent cohorts. 
7.4.3 Calculating peptide peak areas via SKYLINE  
The peptide peak areas were calculated using Skyline software 19. A Skyline library was 
built for each region of interest, providing information on identified peptides, including their m/z. 
After peptide library construction, LC-MS data files related to the different studied regions and 
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conditions were imported into their corresponding Skyline projects. For peptides present in the 
library, corresponding extracted ion chromatograms (XIC) were generated from every single LC-
MS file by SKYLINE. The integrated peak areas of XIC were used for peptide quantitation. The 
peak areas of signals corresponding to different charge states of the same peptide were summed. 
The summed peak areas were log2 transformed and exported to Microsoft Excel for further 
statistical analysis. This transformation was performed to ensure that the data follows a normal 
distribution (which is a required condition for several downstream statistical methods). Correlation 
between the two independent cohorts was evaluated by comparing the mean peak area values 
corresponding to peptide signals acquired from both the cohorts via Pearson correlation factor 
using MATLAB. 
7.4.4 Statistical rationale for peptide quantitation  
Peptide quantitation data exported from Skyline (N=3 for cohort 1 and N=5 for cohort 2) 
was normalized using locally weighted regression analysis. Second cohort intended to validate 
findings from the first cohort, the data were analyzed within and between cohorts.  Normalization 
was performed using the online tool Normalyzer 20. This tool performs a locally weighted 
regression (LOESS) to account for systematic bias in the dataset. An unpaired, 2-tailed Student’s 
t-test with equal variance was used to identify the significantly different peptide levels in the 
control and test groups for both conditions (ProteomeXchange Consortium via the PRIDE). The 
peptides that fell below the set value (p ≤0.05) in both independent cohorts were identified to be 
significant. Since only the peptides that had p ≤0.05 in both the cohorts were considered, a further 
multiple testing correction was not performed. The composite prohormone profile difference 
between the treatment and control groups for both cohorts were evaluated by summing the peak 
areas of the detected endogenously cleaved peptides from a given precursor protein and comparing 
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the summed areas. An unpaired, 2-tailed Student’s t-test was performed on the resultant total 
precursor protein values and a cutoff of p ≤0.1 was used to find proteins with significantly different 
levels. Even in this case, only the precursor proteins that had p ≤0.1 in both the cohorts were only 
considered. For the animal experiments, a 2-way repeated-measures ANOVA was used to analyze 
the chronic effects of treatment. Acute effects of M65 following OIH were evaluated using 2-way 
ANOVA. Analyses were performed in Sigmastat.  
 
7.5 Results  
7.5.1 Behavioral model validation  
The study was performed twice on two independent animal cohorts treated and assayed 
one year apart (Ntotal = 120 animals; Cohort 1: 3 biological replicates x 4 conditions x 5 animals 
per replicate = 60; Cohort 2: 5 biological replicates x 4 conditions x 3 animals per replicate = 60). 
The second cohort was intended to validate findings from the first cohort and the data were 
analyzed within and between cohorts. To induce chronic migraine-associated pain, animals were 
given an intraperitoneal (IP) injection of the known human migraine trigger, NTG (10 mg/kg) 
(migraine), or vehicle (migraine-VEH) every other day for 9 days (5 administrations total) (Figure 
7.1B). On the treatment days, mice were tested before NTG administration; NTG, but not 
migraine-VEH, produced a significant basal mechanical hyperalgesia (Figure 7.1D). For OIH, 
mice were treated twice daily with morphine or vehicle (OIH-VEH). On days 1-3 they received 20 
mg/kg morphine via subcutaneous (SC) injection, and on day 4, 40 mg/kg morphine (Figure 7.1C). 
Mechanical responses were determined prior to the morning injection; morphine treatment also 
produced a significant mechanical hyperalgesia (Figure 7.1E). Targeted nervous system regions 
(Figure 7.1A) were collected from both cohorts 18-24 h after the final drug/control treatment, and 
processed as shown in Figure 7.2. 
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7.5.2 Pain-related peptide complement as detected by liquid chromatography (LC)-tandem 
mass spectrometry (MS/MS) 
Endogenous peptide de novo sequencing facilitated by LC-MS/MS and followed by 
bioinformatic data interpretation led to the structural characterization of >1500 chemically unique 
peptides in morphologically defined regions of the central and peripheral nervous systems that are 
associated with nociceptive and emotional pain processing as follows: TN (605), NAc (550), DH 
(528), RVM (150), TG (1376), H (967) and PAG (156). A high degree of overlap between detected 
peptides in region-specific subsets was observed (Figure 7.3C). This data represents the most 
extensive cataloging to date of endogenous peptides relevant to migraine and OIH. Pain-related 
regions of the nervous system previously investigated for their native peptide complement under 
different biological paradigms are the DH, H, and NAc, while the peptidome of other regions tested 
here have not been previously described in the literature. Comparing against the neuropeptide gene 
expression data found in the Allen Brain Atlas 21, these results validate the presence of final gene 
products in the DH, H, NAc and PAG regions, and provide new insights on neuropeptides in the 
TG and TN region that have not been not profiled previously.  
7.5.3 Quantitation of neuropeptide dynamics 
Following peptide identification, quantitation of peptide levels was performed using 
Skyline software 19. Skyline spectrum libraries were built for each assessed brain region based on 
MS/MS data from the peptide identification experiment described above. The two animal cohorts 
described in the behavioral section were quantified separately; results from the initial discovery 
cohort were independently validated by the results obtained from the second cohort. The tissue-
specific data sets demonstrated a strong positive correlation between treatment groups and animal 
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cohorts (Pearson’s correlation factor (ρ) between 0.5-0.9), with the exceptions of the TG (ρ = 0) 
and NAc (ρ = 0.3-0.4). Among the peptides with quantifiable signals and detected in at least half 
of the biological replicates  (1356 peptides for the migraine group and 1397 peptides in the OIH 
group) from the samples collected in both the cohorts, 16 were significantly different (p ≤0.05) 
between the migraine/migraine-VEH and OIH/OIH-VEH groups. Compared to the migraine-VEH 
group, NTG-treated animals showed a significant increase or decrease in the following peptides in 
different regions (with full name and UniProt accession numbers in parenthesis): DH – CGRP [83-
119] (Calcitonin gene related peptide1 Q99JA0) and SCGI [356-374] (Secretogranin-1 P16014), 
PAG – PENK A[197-208] (Pro-Enkephalin A- P22005), TG – HBA1[111-142] (Hemoglobin 
Subunit alpha1 Q91VB8) and MCTP4[208-228] (Mast cell protease-4 P21812), NAc – 
CLTA[181-204] (Clathrin light chain A- O08585) and TUBB5 [137-167] (Tubulin beta-5 P99024) 
(Figure 6.3A). Similarly, animals with symptoms of OIH showed significant increases or decreases 
in the following peptides in various tested regions: DH – NPY[29-64] (Pro-Neuropeptide Y 
P57774), TKN[101-107] (Pro-Tachykinin  
P41539) and SCGI [333-355] (Secretogranin1 P16014), TG –TMSB10[28-44] (Thymosin-β 10 
Q6ZWY8), PAG – proSAAS [45-59] (Q9QXV0)and SCG1[437-454](P16014), TN – SCG [333-
355] (P16014) and PENKB [166-170] (Pro-EnkephalinB/Pro-Dynorphin-O35417), PAG –and 
NAc – AN32A [1-11] (Acidic nuclear phosphoprotein pp32-  
O35381) (Figure 7.3B). Since only the peptides with a p-value ≤0.05 in both cohorts were chosen, 
a further false discovery rate (FDR) correction was not applied. In summary, significant 
differences in peptide levels were found in the DH, NAc, TG and PAG regions for the migraine 
model, and in the DH, NAc, TG, PAG and TN regions for the OIH model.  
128 
 
HBA1 [111-142] (Q91VB8), identified here, is a novel peptide candidate that has not been 
reported in any of the previous pain-related studies and could potentially be involved 
mechanistically in chronic pain disorders 22 due to its similarity with neokyotorphin peptides. Also, 
in the current study, we observed a significant change in the level of a 7-residue-long peptide, 
(TKN[101-107])(P41539), in the DH region of the migraine model, compared to the control. This 
C-terminal fragment of the longer Neurokinin-A peptide is also a novel candidate and shares the 
same C-terminal sequence (Phe-X-Gly-Leu-Met-NH2) with other known peptide agonists of the 
tachykinin receptor.  
Interestingly, seven of the peptides (Migraine: DH-SCGI [356-374]( P16014) and PAG – 
PENK A[197-208](P22005); OIH: NAc – AN32A [1-11]( O35381); PAG – proSAAS [45-
59](Q9QXV0), SCG[437-454](P16014); DH- TKN[101-107] (P41539) and TN- SCG [333-355]( 
P16014)) with significantly altered levels between migraine/migraine control and OIH/OIH 
control groups showed differences in the opposite direction between the two cohorts measured. 
Because we detected more than 1500 peptides, and only a small subset of the same peptides was 
found to be significantly different among tested conditions, it is likely that these peptides are 
significant, but the specific levels could be impacted by biological rhythms, seasonal changes or 
other variables.  
7.5.4 Functional classification of migraine and OIH-relevant precursor proteins 
The precursor proteins (not just prohormones) for the significantly changed peptides in 
cohort 1 and cohort 2 were considered for functional classification. From this list of proteins, the 
ones that showed up consistently in both cohorts were then subjected to gene ontology (GO) 
classification. This resulted in 31 (24 if the same protein from different regions is counted only 
once) precursor proteins for migraine and 24 (18 if the same protein from different regions is 
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counted only once) for OIH (corresponding to peptides with p ≤0.05, Table 7.1). These did not 
match with the peptide numbers for two reasons. 1) If a different peptide from the same precursor 
protein was significantly changed in cohort 1 and cohort 2, we did not consider the peptide to be a 
hit since it was not consistent in both the cohorts; however, the precursor protein was taken into 
account for GO classification. 2) There are several peptides that map to multiple distinct proteins 
and we cannot know which one they belong to; thus, each of them was considered separately. 
These 31 and 24 precursor proteins corresponding to migraine and OIH conditions, respectively, 
were evaluated for GO using PANTHER analysis 23. We found that migraine primarily induced 
changes in cytoskeletal proteins, signaling molecules, nucleic acid binding, oxidoreductase, 
receptor, transfer/carrier protein, isomerase and membrane traffic proteins. OIH also 
disproportionally affected signaling proteins, as well as receptor, transporter, oxidoreductase, 
transfer/carrier protein, isomerase and enzyme modulating class of proteins. Intriguingly, six 
precursor proteins (determined by the overlap between protein classes among treatment groups 
from PANTHER analysis) were common to both migraine and OIH treatments in both cohorts, 
and include SCG, PENK, proCGRP, Vaccinia growth factor (VGF) and Peptidyl-prolyl-cis-trans-
isomerase-A. 
7.5.5 Neuropeptide prohormone composite of the migraine and OIH conditions  
Prohormone processing often creates multiple biologically active peptides; while expected 
peptides from a prohormone are cleaved, they can be differentially packaged and transported, 
released at different sites, and thus, have different activities and lifetimes. Considering that the 
additive effects of subtle changes in the levels of individual peptides may lead to significant 
cumulative effects in the system, we quantified the precursor protein-peptide composites 
(cumulative changes in detected peptides from a prohormone) for both cohorts. For this profiling 
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effort, the sum of detected peptide signals (peak areas corresponding to peptide ions as measured 
by a mass spectrometer) corresponding to mature, endogenously cleaved (based on known 
prohormone processing rules) and detected peptides from a given prohormone were compared 
between the migraine/migraine-VEH and OIH/OIH-VEH groups (Figure 7.4A). Using this 
approach, a total of 6 prohormones were found to correlate with migraine and/or OIH conditions 
from their respective controls: Vasoactive Intestinal peptide (VIP), PACAP, thyrotropin-releasing 
hormone prohormone (proTRH), PENK, SCG and proSAAS (Figure 7.4C). Specifically, for 
migraine: VIP and SCG2 in the NAc, PACAP, SCG1 and proTRH in the PAG, and PENK in the 
DH; and for OIH: VIP in the NAc, SCG, proSAAS and PACAP in the PAG, and SCG in the TN 
and DH, were significantly changed between the treated and control groups (p ≤0.1) in both cohorts 
(Figure 7.4B). The only individual peptide that was from one of the above-mentioned prohormones 
and also significantly altered by itself was PENK A[197-208](P22005) in the PAG for the migraine 
model. In all other prohormones, the individual peptides constituting the prohormone did not show 
any significant change whereas the composite profiling was significantly different. The current 
discovery could provide more insights about the role of the NAc in pain processing. Although 
PACAP was found in several nervous system regions, significant differences in its derived peptide 
levels were only observed in the PAG in both the migraine and OIH models. Prohormone level 
changes correlated to migraine were observed for proTRH-releasing hormone exclusively in the 
PAG, although proTRH-derived peptides were also detected in examined tissues, except the TG. 
Another migraine-exclusive change in composite prohormone level involves PENK in the DH. In 
contrast, the OIH condition was characterized by composite proSAAS peptide level changes 




7.5.6 Validation of detected neuropeptide localization in the nervous system 
To verify that differentially detected prohormones in the migraine and OIH models are 
present in the analyzed regions of the nervous system, we checked the gene expression profiles of 
the DH, H, NAc, and PAG found in the Allen Brain Atlas 21, as well as in the literature. This 
comparative analysis indicates that genes or transcripts corresponding to the most detected 
peptides in this study are indeed expressed in the DH, H, NAc, PAG and TG. However, a few of 
them, such as Macrophage migration inhibitory factor (MIF), AN32A and VIP in the NAc were 
not expressed in that region according to the Allen Brain Atlas. Thus, our MS findings revealed 
that these peptides might have been transported to the NAc from a different region of the nervous 
system.  
7.5.7 In vivo validation of overlapping pain mechanisms for migraine and OIH  
To validate the hypothesis that there are overlapping mechanisms between chronic 
migraine and OIH, we examined the effect of PACAP, one of the prohormones with a peptide 
composite profile that was similarly altered in both the migraine and OIH groups (Figure 7.4B and 
7.4C), within our behavioral models. PACAP can bind to three different receptors; however, 
because PAC1 is the receptor most commonly associated with migraine-related effects 24-25, we 
tested the PAC1 inhibitor M65 in our chronic migraine and OIH models. Mice for cephalic 
(periorbital) mechanical responses before (basal) and 2 h post-NTG treatment. M65 (0.1 mg/kg, 
SC) was administered 1 h and 30 min post-NTG/VEH injection. Animals were treated every other 
day for 9 days, but only tested on days 1, 5, and 9. Chronic intermittent NTG treatment induced 
periorbital allodynia basally (Figure 7.5A) and 2 h post-treatment (acute responses, Figure 7.5B); 
these effects were completely blocked by M65. For OIH, mice were treated as above for 4 days 
with morphine or vehicle. Periorbital allodynia was assessed on days 1 and 3 of treatment, and 18 
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h following the final injection (day 5, Figure 7.5C). Following the baseline assessment on day 5, 
mice were injected with vehicle or M65 and assessed 30 min later. Like its effects in the migraine 
model, M65 completely inhibited OIH (Figure 7.5D). Our quantitative MS data demonstrate 
differences in PACAP in samples from both models and controls. The pharmacological and 
peptidomics measurement outputs together validate our screening approach and point to PACAP 
as one of the key prohormones involved as an overlapping mechanism of chronic migraine-
associated pain and OIH.  
7.6 Discussion  
Currently available opioid-based therapies are highly addictive, and over-prescription has 
led to a devastating public health crisis. In the United States, morphine, hydrocodone, and 
oxycodone are still regularly prescribed for headache 3-4, and while they may be effective acutely, 
chronic use results in more frequent and severe headaches that are difficult to treat 3-4. Medication 
overuse headache is a form of OIH, and approximately 15% of migraine patients develop this 
disorder 26. The primary treatment for this type of OIH is withdrawal from opioids; however, 
clinical studies have reported a 20-50% relapse rate within the first year of withdrawal 27-28, and 
the majority of patients relapse within the first six months 27. There is clearly a need to understand 
the mechanisms that underlie the interaction between opioids and migraine in the effort to prevent 
further drug abuse.  
The major goal of the current work was to combine behavioral pharmacology and a large-
scale LC-MS approach to look for overlapping mechanisms between chronic migraine and OIH. 
Our results have provided novel insights on the role of neuropeptides and neuropeptide precursors 
in migraine and OIH independently, as well as determined the overlapping peptidomic changes 
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between these two disorders. Of the small subset of neuropeptides that we identified in both 
chronic migraine and OIH, we targeted PACAP for further characterization. We validated this 
target in both of our models of chronic migraine and OIH, thus bringing the research back to 
behavioral endpoints. PACAP has been identified as a target for migraine, but has never been 
considered for OIH, and our work indicates that it may be a bridge linking these two highly 
prevalent disorders.  
Although the epidemiology of migraine has been investigated for several decades 1, the 
molecular events leading to this neurological disorder are not fully characterized. Some studies 
have investigated the differences in individual neuropeptides associated with migraine. The best 
characterized example is CGRP, the levels of which are significantly increased in the venous blood 
during a migraine attack, as well as in the interictal period in chronic migraine patients 6. 
Furthermore, neuropeptides from prohormones such as cholecystokinin 29 have also been 
implicated in the development and maintenance of OIH. However, a limitation of examining the 
role of individual peptides in a disease state is the need to decide a priori which peptides will be 
investigated. In addition, most studies utilize targeted approaches, often relying on indirect 
measurements using molecular probes such as immunohistochemistry (IHC), which are prone to 
false positives due to cross-reactivity. Moreover, the antibodies used in IHC studies bind to a 
relatively small, specific epitope of the peptide of interest and may not be able to discriminate the 
full-length or post-translationally modified biologically active peptides versus their truncated (and 
potentially inactive) versions.  
To overcome these limitations, we utilized a non-targeted,  label-free MS-based approach 
to profile a large peptide complement of the nervous system regions of interest and measure the 
change in levels of identifiable peptides. To increase the statistical power and test for the 
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reproducibility of our results, we tested and measured two independent cohorts, revealing a high 
level of correlation between the cohort results while also validating the newly discovered peptide 
subsets correlated to migraine and/or OIH conditions. The quantitation results obtained from our 
experiments provide convincing evidence that differences in the levels of several peptides and 
precursor proteins correlate with migraine and OIH.  
Several previous studies have shown that peptides from prohormones such CGRP 30 (in 
plasma and TG), NPY 31 (in dorsal root ganglia and DH), and PENK/POMC 32-33 (in H) are directly 
associated with migraine and other pain states. We observed significantly higher levels of full-
length CGRP peptide (CGRP[83-119])(Q99JA0) in the DH region in the migraine model. 
Furthermore, in the OIH group, we found a significant decrease in PENK in the TG. YGGFL, a 
potential biomarker candidate identified in the current study, also known as Leu-enkephalin, is a 
biologically active peptide derived from PENKB[166-170](O35417) prohormone. Mansour et al. 
34 have shown that the YGGFL core is necessary and sufficient for a peptide to act as an agonist 
for both µ- and δ-opioid receptors. A decrease in the endogenous opioid would correspond with 
increased pain sensitivity. As a corollary to this result, we have previously demonstrated that 
activation of the δ-opioid receptor can inhibit migraine-associated hyperalgesia in mice 35. In 
addition, we also observed that Pro-NPY-derived peptide (NPY[29-64])(P57774) was 
significantly higher in the OIH groups relative to vehicle controls in the spinal cord. NPY has been 
implicated as an endogenous pain-relieving peptide 31, 36-37 and shown to be regulated in response 
to alcohol and drug abuse 38, and its alteration in the OIH model may serve as a compensatory 
response to the hyperalgesia induced by chronic morphine. 
Intriguingly, HBA1[111-142](Q91VB8) was significantly altered between the migraine 
treatment and control groups. Several studies have demonstrated the bioactive role of hemoglobin-
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derived peptides. Particularly, the 4-8 residue-long hemorphin and neokyotorphin peptides were 
shown to produce opioid-like activity 39. HBA1[111-142](Q91VB8), a C-terminal peptide of the 
hemoglobin subunit-α, shares the terminal 5 residues (Thr-Ser-Lys-Tyr-Arg) with neokyotorphin, 
which exhibits analgesic properties similar to leu-enkephalin, a well-known endogenous opioid 
peptide 22.  
Peptides of the tachykinin family are well known to be involved in relaying pain signals. 
Substance P (TKN [58-68])(P41539) is an 11 amino acid-containing peptide that plays a major 
role in the transmission of nociceptive input 40. Neurokinin-A (TKN[98-107])(P41539) is another 
peptide from the same precursor protein and is involved in pain perception 41. Both act as an agonist 
for the tachykinin receptor. The binding of these peptide ligands to the receptor is associated with 
the transmission of stress, pain, muscle contraction and inflammation signals 40. The known 
tachykinin receptor peptides possess a common C-terminal structure (Phe-X-Gly-Leu-Met-NH2). 
In the current study, we did find TKN[101-107](P41539), a C-terminal amidated peptide that 
contains the above mentioned common terminal amino acids. 
Other peptides with significantly different levels within our migraine or OIH models were 
derived from functionally distinct proteins such as SCG, proSAAS, Thymosin-β, Acidic nuclear 
phosphoprotein, Tubulin-β, Clathrin light chain A, and mast cell protease. Though not directly 
related to pain mechanisms, the proteins SCG, proSAAS and Thymosin-β are known to produce 
bioactive peptides that mediate secretory granule formation, wound healing, inflammation and 
maintenance of the circadian rhythm 42-44. The peptides identified from these precursor proteins in 
the current study could be the novel targets in studies of chronic pain disorder mechanisms. Lastly, 
some of the precursor proteins such as Tubulin-β, Clathrin light chain A and mast cell protease do 
not have previous evidence of producing signaling peptides.  It is known that peptides transiently 
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exist inside of cells proteasome, a multisubunit complex that converts proteins into peptides. It is 
thought that most proteasome-produced peptides are rapidly degraded in cytosol with a half-life 
of several seconds, while some bind peptide transporters for translocation into ER where they bind 
to major histocompatibility complex I, and then transported the cell surface to serve in antigen 
presentation. At any given snapshot of time when dissection occurred, it is reasonable to expect a 
repertoire of peptide products of protein catabolism in the sampled tissue. Besides, restructuring 
of neuronal nets under pathophysiological conditions is not uncommon and would include protein 
turnover. 
Mass spectrometry cannot inform on the origin of detected peptides beyond their 
association with a protein/s. For peptide quantitation, we standardize sample collection 
(dissection/tissue transfer time, tissue amount and location by stereotaxic coordinates) and apply 
currently the most advanced method of tissue preservation intended to halt postmortem protein 
degradation by rapid heat deactivation 45. As with any study, there is an assumption here, and it is 
that postmortem protein degradation, if happens, has similar extent in all biological replicates 
tested. Future studies equipped with this new knowledge on potentially affected peptides may 
focus on investigation of involvement of specific proteins into migraine/OIH paradigm. 
As one possibility for the difference in the direction of change for several peptides, there 
was a significant seasonal difference in the collection of cohort 1 and cohort 2 samples, and this 
disparity can be in part explained by organism adaptation to slightly different environmental 
conditions. These seven peptides are truncated versions of full-length mature neuropeptides 
derived from prohormones such as SCG, Pro-TKN and proSAAS. Three of the seven peptides are 
from the prohormone SCG, which is known to have unconventional cleavage sites (non-dibasic) 
46. The SCGs do not solely serve as peptide precursors and likely have other functions 46. The 
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variable complex cleavage patterns may have resulted in differential changes in levels for the 
peptides derived from SCG. Regardless of the reasons, the significant changes we observed 
suggest that these peptide levels are sensitive to the pathophysiological paradigms tested. 
Comparing the composite prohormone profile also revealed some unexpected candidates 
that could serve as bridges between chronic migraine and OIH. The sum of the peak areas of the 
endogenously cleaved peptides from the prohormone VIP were significantly different between the 
control and treatment groups of migraine and OIH in the NAc region. VIP and PACAP share 
homology and are both potent vasodilators 47. However, unlike PACAP, infusion of VIP does not 
induce migraine 48. VIP has also not been heavily implicated in morphine-related effects, although 
infusion of VIP into the brain can decrease morphine-induced antinociception 49. Changes in VIP 
levels in the NAc could indicate that the peptide plays a role in the emotional response to 
hyperalgesia induced by chronic morphine or NTG and bears further exploration.  
PACAP acts as a vasodilator and has a similar physiological role to CGRP in inducing 
migraine 25, 47, 50. In the current study, we did notice a significant difference between the cumulative 
peptide signal corresponding to PACAP prohormone in the PAG between the control and treatment 
groups of both migraine and OIH. This similarity in the change of cumulative peptide signal values 
for both migraine and OIH groups strengthens the hypothesis that there could be a common 
underlying mechanism for both disorders. To further elucidate the role of PACAP in chronic 
migraine and OIH, we tested a PAC1 inhibitor within the studied models. Pharmacological 
inhibition of the PACAP receptor, PAC1, blocked hyperalgesia induced by either chronic NTG or 
morphine. Although PACAP has been implicated in migraine pathogenesis, it has not yet been 
identified as a contributing factor to OIH. Our results indicate that PACAP could be an overlapping 
mechanism through which opioid treatment can lead to migraine chronification. These results have 
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important translational significance, as the PACAP-PAC1 system is currently being targeted for 
pharmacological treatment of migraine 25, 47, 50, and our results indicate that these therapies could 
also be effective in OIH and in medication overuse headache induced by opioid treatment. 
Moreover, recent studies have also shown that administration of PAC1 receptor agonist at the bed 
nucleus of stria terminalis (BNST) can facilitate relapse following extinction of cocaine-seeking 
behavior 51 which further strengthens our claim on mechanistic role of PACAP in addiction. 
Overall, this study is the first massive exploratory neuropeptide characterization consisting 
of more than 200 LC-MS experiments resulting in quantitative analysis of around 1500 peptides 
to assess their association with migraine and OIH. Our results confirm and expand our 
understanding of the involvement of known and suspected molecular players in migraine and OIH 
and add important details on other peptides. Our data identify lead peptides and prohormones that 
mechanistically bridge the gap between opioid use and migraine chronification and serve as a solid 
foundation for future studies related to pain processing. Our study also identifies potential 
therapeutic targets common to both migraine and OIH, suggesting that a shared treatment 
procedure that works for both the disorders simultaneously could be developed. Hence, this work 
not only serves to identify peptide dysregulation in various regions of the pain pathway, but also 








Fig. 7.1: A) Nervous system regions collected for the peptide quantitation analysis. DH, dorsal 
horn; H, hypothalamus; NAc, nucleus accumbens; PAG, periaqueductal grey; RVM, rostroventral 
medulla; TG, trigeminal ganglia; TN, trigeminal nucleus caudalis. Treatment paradigm for 
inducing B) migraine and C) OIH. Chronic NTG and chronic morphine both produce hyperalgesia. 
Responses to mechanical von Frey hair stimulation was determined prior to drug/vehicle injection. 
D) Mice treated every other day with NTG (10 mg/kg, IP). E) Mice treated with morphine twice 
daily (days 1-3, 20 mg/kg, day 4, 40 mg/kg, SC). Both data sets were analyzed by two-way 
repeated measures ANOVA, p<0.001 time, drug, and interaction, ***p <0.001 as compared to 










Fig. 7.2: Experimental design and workflow for tissue collection and peptide extraction followed 



































Fig. 7.3: Select peptide level changes as determined by quantitative mass spectrometry for A) 
migraine and B) OIH models. *p ≤0.05, **p ≤0.01. The histogram values represent the Log2 
transformed value of each peptide signal. Error bars represent standard deviation of mass 
spectrometric signals corresponding to the respective peptides. Full list of altered peptides in given 
in Table S3. C) Chord diagram of neuropeptide overlap detected among regions of the nervous 
system: H: hypothalamus; PAG: periaqueductal grey; TG: trigeminal ganglia; TN: trigeminal 
nucleus; DH: dorsal horn; RVM: rostroventral medulla; NAc: nucleus accumbens. In this figure, 
the thickness of the lines between two regions is directly proportional to the extent of overlap 
between two regions. D) Functional classification of select proteins affected by migraine and OIH 
conditions. Protein selection was based on detection of significant level differences among protein-
derived peptides detected in samples of the nervous system regions collected from migraine and 










Fig. 7.4: Composite prohormone profiling: A) An example of proSAAS prohormone with the 
detected, quantified peptides originated from conventional mono/dibasic cleavage sites (i); 
quantification of the prohormone from additive signal of detected constituent peptides of proSAAS 
for the OIH model in the PAG (ii). B) Overlap of the prohormones with the composite prohormone 
signature significantly different (p ≤0.1) between the treatment and control groups for both 
migraine and OIH. VIP, SCG and PACAP are common to both migraine and OIH conditions. 
proTRH and PENK are exclusive to the migraine group whereas proSAAS is exclusive to the OIH 
group. C) Studied regions labeled with the prohormones that are significantly different between 


















Fig. 7.5: PAC1 inhibition by M65 blocked pain induced by chronic NTG and morphine. To induce 
chronic migraine-associated pain, mice were treated every other day, but periorbital allodynia was 
determined only on days 1,5, and 9. Allodynia was assessed before treatment (A; basal responses) 
and 2 h after drug administration (B; post-treatment responses). M65 (0.1 mg/kg SC) or vehicle 
(VEH) was injected 1 h, 30min post-NTG/VEH. (A) M65 blocked the development of basal 
hypersensitivity, 2-way repeated measures ANOVA, p <0.01 treatment and interaction, ***p 
<0.001 as compared to VEH-VEH on day 1; and (B) acute NTG-induced allodynia, 2-way repeated 
measures ANOVA, p <0.001 treatment only. (C) To evoke OIH, mice were administered morphine 
or vehicle twice daily for 4 days (days 1-3, 20 mg/kg; day 4, 40 mg/kg, SC), but periorbital 
allodynia was only assessed on days 1 and 3 of treatment, and 15-18h after the final treatment (day 
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5). Morphine treatment caused significant periorbital allodynia, 2-way repeated measures 
ANOVA, p <0.01 drug, time and interaction, **p <0.01, ***p <0.001 as compared to VEH-VEH 
on day 1. (D) Administration of M65 24 hours after the last injection of morphine/VEH (day 5) 
reversed OIH, 2-way ANOVA, p <0.01 pretreatment (VEH/morphine), drug (M65/VEH), and 
interaction, ***p <0.001. N = 6/group. PACAP is an overlapping mechanism involved in the 







Table 7.1 Precursor proteins that correspond to the significantly changed peptides for the migraine 
and OIH models. For this analysis, the list of precursor proteins that are common to both cohort 1 
and cohort 2 only were considered. (The entire peptide and protein tables with the p values and 
fold-change values can be found in the supplementary information of the manuscript: Mol. & Cell. 
Proteomics 2019, 18 (12), 2447 LP – 2458.) 
 
Region Protein Name (Migraine) Protein Name (OIH) 
DH Secretogranin I Secretogranin II 
Pro-Enkephalin A/B Secretogranin I 
Calcitonin gene-related peptide Pro-Enkephalin A/B 






H Secretogranin I Secretogranin II  
Eukaryotic translation initiation factor Neuro VGF 
 
Neuroendocrine protein 7B2 
 
ProSAAS 




Clathrin light chain* Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
Serine/arginine-rich splicing factor Vasoactive intestinal peptides 
Tubulin beta-2A chain* Peptidyl-prolyl cis-trans isomerase* 





Table 7.1 (cont.) 
 
 








Tubulin beta-6 chain 
 
Tubulin beta-5 chain * 
 
Tubulin beta-4B chain * 
 
Calcitonin gene-related peptide * 
 
PAG Pituitary adenylate cyclase-activating 
polypeptide 
ProSAAS 





TG 40S ribosomal protein S12* Thymosin beta-10 
Mast cell protease 4 Apolipoprotein A 
Alpha Globin 
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Pruritus, also known as itch, has been estimated to afflict approximately 16% of the population1 
and can be a significant symptom of many disorders, including chronic conditions like psoriasis, 
atopic dermatitis, and cholestasis. The symptoms of pruritus are typically characterized as an 
irritating sensation that causes the victim to scratch the affected area and, when chronic, can cause 
significant distress to the point of impairing the affected individual’s quality of life. Unfortunately, 
chronic pruritis is an important health issue for which we do not have reliable treatments, partly 
because we do not yet understand the wide range of molecular players involved in the transmission 
of itch sensation from the peripheral to central nervous system (CNS). 
Itch can be classified into four categories: neurogenic, psychogenic, neuropathic, and 
pruritoceptive, with pruritoceptive being the most common type 2. A diverse class of molecules 
have been implicated in the transmission of itch from the primary sensory neurons to higher-order 
spinal and brain structures, including amines, interleukins, neuropeptides, cannabinoids, and 
eicosanoids 3. The itch-producing stimulus is first detected in the skin by primary sensory neurons, 
which then transmit this information to central neurons in the spinal or medullary dorsal horn (DH) 
neurons. These afferent fibers that innervate the skin can be classified as either Aβ, Aδ, or C fibers, 
based on their size, transmission speed, and myelination status 4. Most well-characterized 
pruritoceptive primary afferents are unmyelinated, small diameter C-fiber neurons 5-6.  
Primary sensory neurons within spinal nerves have a single axon that bifurcates and 
projects from the peripheral nerve endings to the DH of the spinal cord, transmitting important 
sensory information to the CNS 4, 6. These neurons have their cell bodies located within the dorsal 
root ganglia (DRG), which are clusters of neurons that lie in the intervertebral foramen of the 
spinal cord 7-9. The sensory information from the external stimuli is transmitted to the CNS through 
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the release of a variety of signaling molecules, including neurotransmitters, neuropeptides, and 
neuromodulators.  
Given the large diversity of neuropeptides, and their ability to serve as neurotransmitters, 
neurohormones, and neuromodulators, the current study focuses on the identification and 
quantitation of those that play a role in the transmission of itch. Neuropeptides are a class of 
signaling molecules, typically about 3–40 amino acid residues in length, that are synthesized and 
released by neurons to modulate various physiological processes in the body. These processes 
include itch, learning, and reproduction; cardiovascular, gastrointestinal, and respiratory control; 
food and water intake; and analgesia and pain 10. Neuropeptides are typically produced from the 
cleavage of larger precursor proteins, which is sometimes followed by enzymatic post-translational 
modifications (PTMs) such as C-terminal amidation 11-12, acetylation 13, phosphorylation 14-15, 
sulfation 16-17, and pyroglutamination 18. Previous studies have shown that several neuropeptides, 
such as substance P (SP) (TAC1[58-68]; P41539), bradykinin (KNG1[380-388]; O08677), 
calcitonin gene-related peptide (CGRP) (CALCA[83-119]; Q99JA0 ), neuromedin B (NMB[47-
56]; Q9CR53), gastrin-releasing peptide (GRP[24-52]; Q8R1I2), and natriuretic polypeptide B 
(ANFB[103-134]; P16860) are linked to pruritus 19-21. However, there has yet to be an untargeted 
study of the peptide repertoire in the DH and DRG regions to identify the dynamics of neuropeptide 
changes in chronic itch. 
Here liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) was used 
for the identification and quantification of neuropeptides. LC–MS/MS is a valuable technique for 
performing peptidomic analyses; complex samples can be simplified by separation and elution on 
a chromatographic column, followed by subsequent analysis and fragmentation on a mass 
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spectrometer 22-24. The resulting fragmentation spectra of the eluted peptides can then be searched 
against a protein database of the studied organism for identification of the peptides 25. 
In this study, we generated two well-described chronic itch models: an atopic dermatitis-
like model, using calcipotriol (MC903), and a dry skin model using Acetone-Ether and Water 
(AEW). Atopic dermatitis, a skin disorder in which eczematous lesions appear on the skin, is 
associated with intense itch 26. MC903 is a synthetic analogue of vitamin D3 that has been shown 
to induce atopic dermatitis-like inflammation and itch when applied topically to the skin 27-29. 
Chronic itch has also been associated with dry skin; mice that have had a mixture of acetone and 
diethyl ether, followed by water, applied topically to the skin show an increase in scratching bouts 
at the affected area 30-31. The peptidomic analysis was performed on both DRG and DH tissues 
from mice that were subjected to MC903 treatment to induce atopic dermatitis-like symptoms, or 
AEW treatment to induce scratching at the affected areas; a label-free quantification was 
performed to determine the relative changes in the abundance of peptides between treated and 
control mice (Figure 8.1).  
8.3 Materials and methods 
8.3.1 Animals 
Twenty, 8-week-old, male B6J WT mice (Jackson Laboratories, https://www.jax.org/; 
stock #000664) were housed on a 12 hour light/dark cycle and fed ad libitum. All experimental 
procedures, including euthanasia, were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee of Washington University School of Medicine, and 




8.3.2 Chemicals  
Reagents and solvents were obtained from either MilliporeSigma (St. Louis, MO) or Thermo 
Fisher Scientific (Waltham, MA), unless stated otherwise. 
8.3.3 AEW (dry skin) model  
Ten mice were shaved on both their left and right thoracic flanks; 5 mice were treated on 
their shaved right flank and the other 5 mice were treated on their shaved left flank. A 1:1 mixture 
of acetone:diethyl ether was topically applied to the treated side in an approximately 1 cm x 2 cm 
area for 15 s followed by milliQ water for 30 s. The treatment was applied daily for 7 d; the 
untreated side served as the control 32.  
8.3.4 MC903 (atopic dermatitis) model  
Ten mice were shaved on either their left or right thoracic flank; 5 mice were treated on 
their shaved right flank and the other 5 mice were treated on their shaved left flank. MC903 (40 µl 
of 0.1 mM in ethanol; Tocris, Minneapolis, MN) was topically applied in an approximately 1 cm 
x 2 cm area under anesthesia (3% isoflurane) to the treated side for 7 consecutive days to induce 
atopic dermatitis-like disease 33; the untreated side served as the control. 
8.3.5 Behavioral assessment  
Animals were video recorded in their cages for 50 min before their first treatment to serve 
as a baseline measurement, and again after the final day of treatment to confirm development of 
spontaneous itch at the treated sites. Scratch bouts directed at the treated sites were quantified from 
the recorded videos for 30 min, starting after a 20-min habituation period. 
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8.3.6 Tissue collection  
On the seventh day, approximately 170-180 hours after the first treatment, 24 (AD) or 17 
(AEW) hours after the final treatment, and immediately after the last behavioral recording, the 
mice were sacrificed and DH and DRG from approximately T4-T10 spinal levels were dissected 
from both the treated and control sides. Immediately following dissection, the DH the DRG were 
stabilized using the Stabilizor T1 system (Denator AB, Uppsala, Sweden) to minimize peptide 
degradation by peptidases 34-35. The stabilized tissues were then stored in a –80 °C freezer until 
prepared for peptide extraction. 
8.3.7 Peptide extraction  
The sampling and peptide extraction approaches were modeled after our prior studies 17, 35. 
The treated and the control samples were pooled such that two tissue samples corresponding to 
either treated or control were combined. Ice-cold LC–MS grade water (400 µL) was then added to 
each of the pooled tissues and homogenized using a pellet pestle cordless motor. The homogenized 
samples were left to incubate on ice for 40 min. Following incubation, the samples were 
centrifuged for 20 min at 16000 × g at 4 °C. Following centrifugation, the supernatant was 
transferred to a new tube, and the pellet was re-suspended in 400 µL of 40:5:5 methanol:formic 
acid (FA):water and left to incubate on ice for 40 min. The sample was then centrifuged for 20 
min at 16000 × g at 4 °C, and afterwards, this supernatant was combined with the supernatant from 
the previous step. The combined supernatants were then evaporated on a SpeedVac evaporator 
(Genevac, Ipswich, Suffolk, UK). While the supernatants were evaporating, the pellets were re-
suspended in 400 µL of 0.25% FA in LC–MS grade water and incubated on ice until the combined 
supernatants were dry (~60 min). The reconstituted pellets were then centrifuged for 20 min at 
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16000 × g at 4 °C. The pellets were discarded, and the supernatants added to the vial containing 
the dried extracts from the previous incubations. 
The samples were loaded onto an equilibrated Pierce C18 spin column (Thermo Fisher Scientific) 
and washed twice with 200 µL of 95:5:0.1:0.01 water:acetonitrile (ACN):FA:trifluoroacetic acid 
(TFA); the peptides were then eluted twice with 50 µL of 50:50:0.1:0.01 water:ACN:FA:TFA and 
twice with 50 µL of 20:80:0.1:0.01 water:ACN:FA:TFA. After eluting the peptides, the samples 
were evaporated until dry on the SpeedVac evaporator. The dried samples were stored at –80°C 
until analysis by LC–MS/MS. 
8.4 Mass spectrometric measurement  
8.4.1 Nano-LC for peptide identification and quantitation  
For the peptide library construction, the pooled samples were reconstituted in 10 µL of 
95:5:0.1 water:ACN:FA and loaded onto an Acclaim PepMap100 C18 trap column at 15 µL/min. 
After 3 min, the trap column was then connected in-line with the analytical column (Acclaim 
PepMap 2 Å, 75 µm × 150 mm, Thermo Fisher Scientific) using a Thermo Scientific Ultimate 
3000 RSLC system. The solvents used were water with 0.1% FA, and ACN with 0.1% FA, as 
solvents A and B, respectively, at a flow rate of 300 nL/min. A 120-min gradient elution was used 
with the following parameters: 0–3 min, 1–1% B, 3–6 min, 1–10% B, 6–90 min, 10–70% B, 90–
100 min, 70–99% B, 100–110 min, 99–1% B, 110–120 min, 1–1% B. For the peptide quantitation, 
the dried samples were reconstituted in 95:5:0.1 water:ACN:FA and then centrifuged for 20 min 
at 16000 × g. An 8-µL sample was then transferred to an autosampler vial, with 7 µL being injected 




8.4.2 Orbitrap parameters  
Top speed data-dependent precursor selection was used on a Thermo Scientific 
Quadrupole-Ion Trap-Orbitrap Fusion mass spectrometer with a cycle time of 3 s. Parent ions were 
scanned with an Orbitrap resolution of 120K with an AGC target of 200,000. Dynamic exclusion 
was used with the following settings: exclusion time = 60 s, mass tolerance = ± 10 ppm, repeat 
count = 3. For the Orbitrap detection, the parent ions were scanned in the range of 200–1400 m/z, 
the fragment ions were scanned with the ion trap detector, a maximum injection time of 35 ms, 
and an AGC target of 10,000. Precursor ions with a charge ranging from +1 to +7 were considered 
and a normalized collision energy of 35% was used for the CID fragmentation. 
8.4.3 Q-TOF parameters  
The samples used for the peptide quantitation were analyzed using a Bruker Impact HD 
QqTOF mass spectrometer equipped with a CaptiveSpray nanosource. Data was acquired with 
MS1, with a mass range of 290–3000 m/z, a cycle time of 3 s, and a scan rate of 1 Hz. An absolute 
intensity threshold of 694 counts was used for spectra collection. 
8.4.4 Peptide library construction  
The .RAW files obtained from the Thermo Orbitrap Fusion were imported into the PEAKS 
8 software (Bioinformatics Solutions Inc., Canada); the spectra were searched against a mouse 
proteome database with 81,515 proteins from UniProt 36. For the database search, the following 
parameters were used: precursor mass tolerance = 10 ppm; fragment mass tolerance = 0.1 Da; no 
enzymatic cleavage; variable PTMs selected, which included acetylation, amidation, 
phosphorylation, half-disulfide bond, pyroglutamination, and methionine oxidation; and a 
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maximum number of variable PTMs. A false discovery rate (FDR) threshold of 1% peptide 
spectrum match was used to filter out the identified peptide sequences. Data are available via 
ProteomeXchange with identifier PXD015949.  
8.4.5 Peptide quantitation via Skyline  
Relative quantitation of the identified peptides was performed using Skyline (version 4.2.0) 
software 37. A peptide library was constructed that consisted of individual peptide details, including 
amino acid sequence, PTMs, m/z, and retention time. After the library construction, the individual 
LC–MS data files corresponding to each of the studied regions were imported into the Skyline 
project. An extracted ion chromatogram (XIC) for each of the peptides present in the library was 
then generated by Skyline from the LC–MS files. The integrated peak areas of the XIC for each 
peptide were then exported to a CSV file for further statistical analysis. 
8.4.6 Statistical analysis  
Following the peptide quantitation, the summed peak areas were subjected to a locally 
weighted regression analysis using the Normalyzer tool 38. The purpose of performing this 
normalization was to account for inter-run variability brought about by sample preparation 
inconsistencies and instrument variability. For normalization, the data is transformed into the 
standard M (log ratio) and A (mean average) scales within a specific treatment group. Then, a plot 
of M vs. A values was constructed and the individual peptide peak areas for each sample were 
corrected based on a locally weighted regression algorithm as described by Chawade et al 38. To 
determine if there was a significant change in peptide levels between the treated and the control 
samples, a student’s t-test was performed; p values that were less than 0.05 were considered 
significantly different. A permutation-based FDR correction was then applied to account for false-
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positive values using the Perseus computational platform (Version 1.6.2.3) 39, in which the values 
that had a q-value of less than/equal to 0.1 were considered. The peptide quantitation workflow 
presented here has been implemented and validated in our prior work 40. 
The principal component analysis (PCA) was performed using the inbuilt statistical package 
(prcomp) of R. Briefly, the dataset was first scanned for missing values. Since PCA cannot handle 
missing values, the missing values for peptide peak areas were imputed based on random draw 
from a truncated normal distribution (RTI) based approach which is known to perform well in case 
of left-censored missing values i.e. values missing due to low intensity/peak area 41. Following the 
imputation, the data is centered to ensure that the first principal component (PC1) does indeed 
describe the direction of maximum variance. PCA was then performed on this centered data. Once 
the PCA was performed, a clustering analysis was performed using the first 3 PCs to identify the 
pairs that capture the maximum variance and separate the two treatment groups. A loadings plot 
was further constructed with the scores corresponding to these PCs and a cutoff of 
1
columns
where columns represents the number of quantified peptides. Given the number of peptides 
quantified in both the regions, this cutoff is between 0.05-0.06. 
8.5 Results 
8.5.1 Behavioral model validation  
Animals were video recorded from above in their cages for at least 1 h at baseline and after 
7 d of treatment for the AEW mice and 5 d of treatment for the MC903 mice. Upon review of the 
videos, the scratch bouts per side for each animal were counted and recorded. When compared 
with baseline or with the untreated flank, all animals showed significantly increased spontaneous 
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scratching directed at the treatment site; confirming that the AEW and MC903 treatments 
successfully produced chronic itch in our model animals (Figure 8.2A, B). 
8.5.2 Itch-related peptides detected by LC–MS/MS analysis  
This study was performed in two different cohorts. The initial cohort consisted of N=3 
replicates per model (AEW and MC903) per condition (treated and control) with tissue from N=1 
animal being used per replicate. Though we did find some encouraging results with peptides such 
as somatostatin-28 (SST[89-116]; P60041), dynorphin B29 (PDYN[221-248], O35417), β-
preprotachykinin C-terminal flanking peptide (TAC1[111-126], P41539), SP (TAC1[58-68], 
P41539), nocistatin (PNOC[98-138], Q64387), and PEN (PCSK1[219-240], Q9QXV0), which 
were differentially regulated in treated vs. control samples (p<0.05), none of the peptides crossed 
the set threshold (q≤0.1) for multiple testing correction by FDR estimation. Therefore, we 
performed a second independent cohort of experiments with a higher number of replicates (N=4 
per condition per treatment) and also a higher number of animals per replicate (tissues of N=2 
animals pooled into one). De novo-assisted database searching followed by quantitation facilitated 
the quantitation of 329 and 354 peptides from the DRG and DH, respectively (Figure 8.2 C). Of 
these total quantified peptides, 266 are from MC903 DRG and 271 from DRG AEW, and 335 
peptides are from DH MC903 and 318 from DH AEW. Moreover, increasing the sample size led 
to an increase in the power (the probability of rejecting the null hypothesis when, in fact, it is false) 
of the hypothesis test used to investigate the differences between the treated and control mice; 





8.5.3 Differentially regulated peptides in itch models  
Among the quantified peptides (Figure 8.2 C) in the DRG and DH (cohort 2, AEW and 
MC903 models), 30 peptides were differentially regulated after accounting for the multiple testing 
correction (q≤0.1) (Table 8.1). All 30 peptides are from the DH of the AEW model and include 
several derived from prohormones such as proSAAS (PCSK1[243-252], Q9QXV0), 
protachykinin-1 (TAC1[72-94], P41539), proenkephalin (PENKA[107-132], P22005), and CGRP 
(CALCA[26-48]; Q99JA0) (Figure 8.2 D). Additionally, we noticed several other prohormone-
derived peptides had a p-value<0.05. Though these peptides did not cross the multiple testing 
correction threshold (q≤0.01) a further careful analysis could reveal their potential role in 
mediating itch. These include: secretogranin1 (SCG1, P16014), cerebellin-1 (CBLN1, Q9R171), 
and tachykinin-3(TKNK; P55099) in DH MC903; proSAAS (PCSK1, Q9QXV0) in DRG AEW; 
and CGRP (CALCA, Q99JA0) and proSAAS in DRG MC903.  
8.5.4 Clustering analysis of the quantified peptides  
Change in the levels of individual peptides / proteins usually does not capture the entire 
picture of the dynamic changes that they undergo under a specific physiological condition. 
Oftentimes a group of peptides or proteins have correlated levels of change or directions of change. 
Here, we performed additional clustering analysis to identify if a particular peptide / group of 
peptides are responsible for differentiation between the treated and control groups. Moreover, 
clustering analysis also identifies if a certain group of peptides / proteins have a similar pattern of 
regulation. First, by using principal component analysis (PCA) (Figure 8.3), a widely used 
technique for dimensionality reduction and cluster visualization 42-44, we were able to distinguish 
between the treated and control group of samples for DH AEW, DRG AEW, and DRG MC903. A 
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further loadings plot analysis was performed to gain more insights into the peptides that had 
contributed to this separation (based on the cutoff described earlier). From this analysis too, several 
prohormone-derived and signaling pathway-related peptides are showed to be contributing 
towards differentiating the control and treated groups: PENK-A (P22005), TAC1 (P41539), CGRP 
(Q99JA0), pituitary adenylate cyclase-activating polypeptide (O70176), and proSAAS (Q9QXV0) 
for DH AEW; CGRP (Q99JA0), neurofilament light polypeptide (NFL-P08551), and mast cell 
protease 4 (Q3UN88) for DRG AEW; CGRP (Q99JA0), SCG (Q03517), mast cell protease 4 
(Q3UN88) and cathepsinB (CATB-P10605) for DRG MC903.  
8.5.5 Functional classification of precursor proteins involved in itch  
Precursor proteins corresponding to the significantly changed peptides (p<0.05, after 
accounting for multiple testing correction (q≤0.1), only from DH AEW) were further grouped 
according to their protein class. These proteins were subjected to a gene ontology (GO) 
classification using PANTHER 45. Though all of the identified peptides fall into 11 different 
classes of precursor proteins, the 30 significantly changed peptides from DH AEW were mapped 
to three classes: signaling molecules, hydrolase, and enzyme modulators (Figure 8.4).  
8.5.6 Validation of detected neuropeptide localization in the nervous system 
To verify that the differentially detected peptides associated with itch are present in the analyzed 
regions of the nervous system, we checked the gene expression profiles of the DH in the Allen 
Brain Atlas. From this analysis, we found that all of the significantly changed peptides do have 
their precursor protein gene expressed in the DH (except for Protein Virilizer homolog (A2AIV2) 
and neuroendocrine protein 7B2 (P12961), for which the expression information was not 
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available). This comparative analysis indicates that genes or transcripts corresponding to all of the 
identified candidates are indeed present in the mouse DH.  
8.6 Discussion 
To the best of our knowledge, this is the first mass spectrometry-based peptidomics analysis of 
models of chronic itch. We performed a comprehensive peptidomic analysis on DRG and DH 
samples from control and treated regions of mouse models for atopic dermatitis and dry skin. The 
quantitation results were analyzed to investigate peptide level changes between the control and 
treated sides of subject animals and statistically significant differences were found after accounting 
for multiple testing correction. Additionally, an unsupervised clustering based on reduced 
dimensions (via PCA) revealed that the change in peptide levels indeed contribute towards 
differentiating the treated vs. control groups in three of the four tested conditions (Figure 8.3). A 
further analysis via loadings plot demonstrated that several known signaling molecules as well as 
important signaling regulators do have a major contribution towards this differentiability. 
Importantly, many of the peptides detected in our study have already been reported to be 
involved in itch, which serves as a validation to our approach. For example, SP acts as a 
neurotransmitter in the spinal cord and induces scratching responses when injected intrathecally 
into mice 46. CGRP serves as a neuromodulator and potentiates glutamatergic itch signals from 
TRPV1+ primary afferents.47 Additionally, these neuropeptides are also released from the 
peripheral terminals of DRG neurons in the skin. There, CGRP and SP have specifically been 
shown to recruit and activate mast cells, respectively, and potentiate chronic itch 48.   
Within the list of peptides that have significantly changed in the DH AEW model after 
accounting for multiple testing correction are two known endogenous neuropeptides and 
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significant portions of two other known full-length neuropeptides. These are PCSK1[243-252] 
(little LEN), PENK[238-259] (P22005), the first 7 residues of hippocampal cholinergic 
neurostimulatory peptide (PEBP1[2-9]; P70286), and the first 22 residues of neuropeptide K 
(TAC1[72-94]; P41539). Additionally, along with PENK[238-259], another PENK-derived 
peptide; PENK[107-132], which contains the sequence for met-enkephalin (PENK[107-111]), was 
significantly changed. 
Little LEN, first identified by Fricker et al. 49, is derived from the prohormone proSAAS. 
Not much is known about the function of this peptide, except that it may have a neuroendocrine 
function. While it has been found in the mouse hypothalamus and pituitary, little LEN does not 
localize to neuropeptide Y-expressing cells or influence feeding behavior like other proSAAS-
derived peptides do 50-51. One recent study has reported that the expression of the proSAAS 
encoding gene, PCSK1N, is enriched in Mrgpra3+ expression in DRG neurons, which are selective 
neurons for detecting itch 52.  
PENK[238-259] and met-enkephalin are peptides derived from proenkephalin-A, a 
member of the endogenous opiate enkephalin family. In general, opiates decrease the sensitivity 
of neurons to pain by inhibiting their firing rates and decreasing neurotransmitter release 10, 53. 
Particularly, the enkephalins play a role in pain regulation at the spinal level through the 
functioning of met-enkephalin interneurons 10, 54. However, it has been noted that while opiates 
provide relief from pain processes, they cause an increase in itch sensation 55. This differential 
sensory response to opiate stimuli has in fact been used to support the idea that there are separate 
sensory pathways for pain and itch sensation. Interestingly, PENK expression has been found to 
be increased within the skin in various skin diseases, including psoriasis 56, which indicates a role 
for PENK in the diseases we were modeling in this study.  
168 
 
Hippocampal cholinergic neurostimulatory peptide is one another candidate that showed 
up to be significantly changed between the treated and control groups. It is derived from 
phosphatidylethanolamine-binding protein 1 and has been shown to modulate acetylcholine 
synthesis through either stimulation of or suppression of acetylcholine transferase, depending on 
location and length of exposure 48, 57. Acetylcholine is a monoamine neurotransmitter that plays 
multiple roles in the nervous system, one of which involves communication between neurons and 
mast cells, which are involved in inflammatory response 48, 58. Within this context, acetylcholine 
has been shown to induce itch in patients with atopic disease compared with pain that is induced 
in controls under the same circumstances 59, suggesting a possible role for an acetylcholine 
modulatory peptide within atopic disease states.  
Finally, the particular shortened form of neuropeptide K detected within our experiments 
has been previously detected and tentatively identified in a peptidomics study comparing levels of 
peptides in the brains of Cpefat/fat mice to wild type controls performed by the Fricker group 60. 
Neuropeptide K is derived from protachykinin, which is also the precursor of the well-known pain 
peptide SP. While TAC1[72-94] (P41539) was not detected in enough samples in the 
aforementioned Fricker study for the difference to be statistically significant, a similar peptide with 
one additional amino acid on its C terminus, TAC1[72-95] (P41539), was. An alternative but 
equally appealing lead to the importance of this finding is that neurokinin A, another peptide 
derived from protachykinin and is expressed in sensory neurons and distributed similarly to SP in 
the spinal cord 61, is formed by cleavage at a nearby dibasic site to our detected peptide. Therefore, 




It is also promising to note that within the gene ontology analysis of the precursor proteins, 
the protein levels that changed the most between treatment and control samples were those that 
were characterized as signaling molecules, enzyme modulators, and hydrolases. Neuropeptides are 
typically produced from the cleavage of larger precursor proteins through a sequence of processing 
steps that  use a variety of enzymes including prohormone convertases, endopeptidase, 
carboxypeptidase, and aminopeptidase. Therefore, in addition to the expected result that the levels 
of signaling molecules are changing between the treatment and control groups, evidence that there 
are changes in proteins that could be used by the cell to synthesize and process specific 
neuropeptide transmitters is a promising result. 
Finally, it might seem paradoxical that the peptide levels are decreasing in the treatment 
groups compared to the control groups when we are hypothesizing that these peptides are involved 
in the transmission of sensory information, including itch. Two aspects of this study make these 
observations more reasonable. First, MS measures the amount of peptide in the tissue at the time 
of sample collection. If a peptide undergoes activity-dependent release, its amount within the tissue 
may decrease. A longer-term use of a peptide within the system could result in more synthesis and 
accumulation. However, it could also result in decreased synthesis as the organism tries to 
modulate its sensitivity to the stimulus over time. Thus, we would expect the amount of a peptide 
involved in sensory transmission within our itch model to change, but the direction of change 
depends on peptide release / synthesis dynamics and is difficult to predict. Additionally, 
neuropeptides involved in signal transmission could originate from either the DRG or spinal 
neurons, making their detection trickier. 
Neuropeptide signaling is a dynamic system in which location, timing, and sampling 
methods all influence which peptides are present, as well as if we can detect that change. The 
170 
 
purpose of our study was to begin the process of identifying peptides to target for follow-up studies 
within itch model systems. Overall, we are hopeful that the increased insight into this complex 
system provided by this work helps to identify important peptide candidates for further 
investigation into the mechanistic processes leading to itch and other peripheral nervous system-







































Fig. 8.2: Number of scratches on the control and treated sides for the (A) MC903 and (B) AEW 
models. (C) Overlap of all the quantified peptides between the DH and DRG regions (in both 
models combined). (D) Select peptides that were significantly different between the treated and 












Fig. 8.3: Volcano plot, PCA, and loadings plots of the (A) DH AEW, (B) DRG AEW, and (C) 












Fig. 8.4: Gene ontology analysis of the precursor proteins corresponding to (A) All the quantified 
peptides and (B) peptides that were significantly different (p,0.05, q≤0.1) in DH AEW. The 
hydrolase, enzyme modulators, and the signaling molecule classes of enzymes are depicted with 









Table 8.1 Peptides and the corresponding precursor proteins from DH AEW after accounting for 
multiple testing correction (q≤0.1). 
 
Precursor Protein with 
Accession Number 













Calmodulin-1 (P62204) A(+42.01)DQLTEEQIAEFKEAFSLFD* 1.875 
Cathepsin B (P10605) IDLPETFDAREQWSN* 2.432 

























isomerase A (P17742) 
EDENFILKHTGPGILSM** 3.838 
V(+42.01)NPTVFFDIT*** 1.488 



















Protachykinin-1 (P41539) DADSS(+79.97)VEKQVALLKALYGHGQIS* 3.012 
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Table 8.1 (cont.) 
 
Protein AF1q (P97783) PIASIHSVDLDLL** 1.022 






Thioredoxin (P10639) VKLIESKEAFQEALAAAGDKLVVVDF* 0.956 
Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1 (Q9R0P9) 
MQLKPMEINPEMLNKVLAKLGVAGQWRFADVL* 0.858 
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